[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fCHAtlvDcw91w-YwVMHIBHkwOxbOphC240y75MrtrKuY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":83,"rows":90},"Leiden University Medical Center",[4],328,false,93,27,222482,48,195,[14,17,19,22,24,26,29,31],{"name":15,"count":16},"Colorectal Cancer",6,{"name":18,"count":16},"Cardiovascular Diseases",{"name":20,"count":21},"Pulmonary Embolism",5,{"name":23,"count":21},"Breast Cancer",{"name":25,"count":21},"Myasthenia Gravis",{"name":27,"count":28},"Diabetes Mellitus",4,{"name":30,"count":28},"Pain",{"name":32,"count":28},"Deep Vein Thrombosis",[34,39,44,49,54,59,63,68,73,78],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT03747159","Synergetic B-cell Immunomodulation in SLE - 2nd Study.","2024-06-07","Belimumab",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06478498","Immune Responses in the Skin After Hookworm Infection","2025-01-01","Necator americanus L3 larvae",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05961059","InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and Zambia","2025-05","2.5 μg InvaplexAR-Detox",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT05784311","Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW)","2025-07","Cefuroxime",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06293339","Durability of Protection After Single Immunisation With GA2 Sporozoites (CoGA-Rechallenge)","2025-07-01","CHMI with 3D7 malaria",{"nctId":60,"briefTitle":61,"date":57,"intervention":62},"NCT05406856","PROTECT: On-line Adaptive Proton Therapy for Cervical Cancer","Cisplatin",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT05324748","Repeated GON Injections in CCH","2025-12","Methylprednisolone",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT05508763","Personalised Therapeutics @LUMC","2026-02","Genetic test for 14 pharmacogenes",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT05274919","Vascular Signature Mapping of Brain Tumor Genotypes","2026-03-31","Additional contrast",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT05851508","The Effecttiveness of Intratympanic Methylprednisolon Injections Compared to Placebo in the Treatment of Vertigo Attacks in Meniere's Disease","2026-05-01","Methylprednisolon",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,139,182,200,226,244,267,285,325,354,385,403,421,439,466,496,514,532,550,568,594,616,634,656,683,701,727,752,775,800,826,844,865,889,907,925,954,972,990,1035,1065,1086,1117,1143,1161,1186,1210,1230,1253,1292,1327,1349,1387,1409,1448,1466,1492,1510,1528,1554,1580,1598,1626,1652,1680,1698,1724,1742,1767,1793,1822,1840,1865,1883,1907,1931,1957,1975,2001,2019,2087,2120,2146,2172,2190,2214,2232,2260,2286,2304,2322,2340,2365,2383,2415,2450,2476,2494,2521,2546,2569,2594,2619,2637,2660,2686,2714,2739,2764,2786,2810,2828,2855,2881,2906,2931,2949,2973,3000,3018,3041,3065,3091,3109,3127,3145,3170,3197,3223,3249,3267,3285,3303,3321,3347,3370,3395,3413,3431,3449,3473,3491,3515,3540,3566,3584,3602,3620,3659,3686,3712,3739,3773,3797,3822,3847,3865,3891,3916,3934,3959,3987,4011,4037,4063,4081,4105,4131,4154,4181,4207,4233,4258,4281,4299],{"intervention":92,"totalTrials":93,"cells":94},"Clindamycin",2,{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":104,"NA":122},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[],{"trials":101,"activeCount":97},[],{"trials":103,"activeCount":97},[],{"trials":105,"activeCount":121,"soonestReadout":111},[106],{"nctId":107,"briefTitle":108,"status":109,"phases":110,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":119},"NCT06172010","Rifampicin Combination Therapy Versus Monotherapy for Staphylococcal Prosthetic Joint Infection","RECRUITING",[88],"2027-03","2028-03","2023-04-01",316,[116,117,118],"Prosthetic-joint Infection","Infection Hip","Infection; Knee, Joint",[92,120],"Rifampicin and levofloxacin",1,{"trials":123,"activeCount":121,"soonestReadout":129},[124],{"nctId":125,"briefTitle":126,"status":127,"phases":128,"primaryCompletion":129,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":137},"NCT06702345","Clostridioides Difficile Controlled Human Infection Model","NOT_YET_RECRUITING",[89],"2026-07-01","2026-12-31","2025-03-01",60,[134,135,136],"C. Difficile","C. Difficile Infection","Controlled Human Infection",[138,92],"Vancomycin",{"intervention":140,"totalTrials":93,"cells":141},"Prednisolone",{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":146,"PHASE3":148,"PHASE4":163,"NA":180},{"trials":143,"activeCount":97},[],{"trials":145,"activeCount":97},[],{"trials":147,"activeCount":97},[],{"trials":149,"activeCount":97},[150],{"nctId":151,"briefTitle":152,"status":153,"phases":154,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":160},"NCT03942887","Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis","UNKNOWN",[87],"2025-04-01","2019-05-03",100,[159],"ANCA Associated Vasculitis",[161,162,67,140],"Rituximab","endoxan",{"trials":164,"activeCount":121,"soonestReadout":169},[165],{"nctId":166,"briefTitle":167,"status":109,"phases":168,"primaryCompletion":169,"completion":170,"start":171,"enrollment":172,"conditions":173,"interventions":179},"NCT05725512","Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages",[88],"2026-07-29","2027-07-29","2024-01-29",490,[174,175,176,177,178],"Recurrent Miscarriage","Recurrent Pregnancy Loss","Habitual Abortion","Miscarriage","Fertility Disorders",[140],{"trials":181,"activeCount":97},[],{"intervention":120,"totalTrials":121,"cells":183},{"EARLY_PHASE1":184,"PHASE1":186,"PHASE2":188,"PHASE3":190,"PHASE4":192,"NA":198},{"trials":185,"activeCount":97},[],{"trials":187,"activeCount":97},[],{"trials":189,"activeCount":97},[],{"trials":191,"activeCount":97},[],{"trials":193,"activeCount":121,"soonestReadout":111},[194],{"nctId":107,"briefTitle":108,"status":109,"phases":195,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":196,"interventions":197},[88],[116,117,118],[92,120],{"trials":199,"activeCount":97},[],{"intervention":201,"totalTrials":121,"cells":202},"Levetiracetam",{"EARLY_PHASE1":203,"PHASE1":205,"PHASE2":207,"PHASE3":209,"PHASE4":211,"NA":224},{"trials":204,"activeCount":97},[],{"trials":206,"activeCount":97},[],{"trials":208,"activeCount":97},[],{"trials":210,"activeCount":97},[],{"trials":212,"activeCount":121,"soonestReadout":129},[213],{"nctId":214,"briefTitle":215,"status":109,"phases":216,"primaryCompletion":129,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":222},"NCT03048084","Seizure Treatment in Glioma",[88],"2028-07-01","2018-02-01",120,[221],"Glioma",[201,223],"Valproic Acid",{"trials":225,"activeCount":97},[],{"intervention":223,"totalTrials":121,"cells":227},{"EARLY_PHASE1":228,"PHASE1":230,"PHASE2":232,"PHASE3":234,"PHASE4":236,"NA":242},{"trials":229,"activeCount":97},[],{"trials":231,"activeCount":97},[],{"trials":233,"activeCount":97},[],{"trials":235,"activeCount":97},[],{"trials":237,"activeCount":121,"soonestReadout":129},[238],{"nctId":214,"briefTitle":215,"status":109,"phases":239,"primaryCompletion":129,"completion":217,"start":218,"enrollment":219,"conditions":240,"interventions":241},[88],[221],[201,223],{"trials":243,"activeCount":97},[],{"intervention":53,"totalTrials":121,"cells":245},{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":250,"PHASE3":252,"PHASE4":254,"NA":265},{"trials":247,"activeCount":97},[],{"trials":249,"activeCount":97},[],{"trials":251,"activeCount":97},[],{"trials":253,"activeCount":97},[],{"trials":255,"activeCount":121,"soonestReadout":52},[256],{"nctId":50,"briefTitle":51,"status":109,"phases":257,"primaryCompletion":52,"completion":258,"start":259,"enrollment":260,"conditions":261,"interventions":263},[88],"2026-01","2023-03-06",344,[262],"Pancreatic Cancer",[53,264],"Metronidazole",{"trials":266,"activeCount":97},[],{"intervention":264,"totalTrials":121,"cells":268},{"EARLY_PHASE1":269,"PHASE1":271,"PHASE2":273,"PHASE3":275,"PHASE4":277,"NA":283},{"trials":270,"activeCount":97},[],{"trials":272,"activeCount":97},[],{"trials":274,"activeCount":97},[],{"trials":276,"activeCount":97},[],{"trials":278,"activeCount":121,"soonestReadout":52},[279],{"nctId":50,"briefTitle":51,"status":109,"phases":280,"primaryCompletion":52,"completion":258,"start":259,"enrollment":260,"conditions":281,"interventions":282},[88],[262],[53,264],{"trials":284,"activeCount":97},[],{"intervention":67,"totalTrials":286,"cells":287},3,{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":294,"PHASE4":309,"NA":323},{"trials":289,"activeCount":97},[],{"trials":291,"activeCount":97},[],{"trials":293,"activeCount":97},[],{"trials":295,"activeCount":121,"soonestReadout":66},[296,305],{"nctId":64,"briefTitle":65,"status":109,"phases":297,"primaryCompletion":66,"completion":298,"start":299,"enrollment":300,"conditions":301,"interventions":303},[87],"2026-06","2022-11-07",50,[302],"Cluster Headache",[67,304],"Saline solution",{"nctId":151,"briefTitle":152,"status":153,"phases":306,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":307,"interventions":308},[87],[159],[161,162,67,140],{"trials":310,"activeCount":97},[311],{"nctId":312,"briefTitle":313,"status":314,"phases":315,"primaryCompletion":316,"completion":316,"start":317,"enrollment":318,"conditions":319,"interventions":322},"NCT04014634","GON-injection for a Sooner and Better Treatment of Cluster Headache","COMPLETED",[88],"2021-08-27","2019-08-01",70,[320,321],"Cluster Headache, Episodic","Greater Occipital Nerve Injection",[67],{"trials":324,"activeCount":97},[],{"intervention":326,"totalTrials":121,"cells":327},"[18F]-FAPI-74",{"EARLY_PHASE1":328,"PHASE1":330,"PHASE2":332,"PHASE3":334,"PHASE4":350,"NA":352},{"trials":329,"activeCount":97},[],{"trials":331,"activeCount":97},[],{"trials":333,"activeCount":97},[],{"trials":335,"activeCount":121,"soonestReadout":340},[336],{"nctId":337,"briefTitle":338,"status":109,"phases":339,"primaryCompletion":340,"completion":341,"start":342,"enrollment":343,"conditions":344,"interventions":349},"NCT07018661","[18F]F-FAPI PET\u002FCT and Laparoscopy in Staging Advanced Gastric Cancer",[86,87],"2028-01","2029-01","2025-07-03",250,[345,346,347,348],"Locally Advanced Gastric Adenocarcinoma","STOMACH NEOPLASM","Gastric Cancer","PET-CT",[326],{"trials":351,"activeCount":97},[],{"trials":353,"activeCount":97},[],{"intervention":355,"totalTrials":121,"cells":356},"Doublet Chemotherapy, Standard Dose",{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":363,"PHASE4":381,"NA":383},{"trials":358,"activeCount":97},[],{"trials":360,"activeCount":97},[],{"trials":362,"activeCount":97},[],{"trials":364,"activeCount":121,"soonestReadout":369},[365],{"nctId":366,"briefTitle":367,"status":109,"phases":368,"primaryCompletion":369,"completion":370,"start":371,"enrollment":372,"conditions":373,"interventions":377},"NCT06275958","DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer",[87],"2028-06","2028-12","2024-07-01",587,[374,15,375,376],"Older Patients","Metastatic Cancer","Candidates for Palliative Chemotherapy",[355,378,379,380],"Doublet Chemotherapy, Dose-reduced","Monotherapy, Standard Dose","Monotherapy, Dose-reduced",{"trials":382,"activeCount":97},[],{"trials":384,"activeCount":97},[],{"intervention":378,"totalTrials":121,"cells":386},{"EARLY_PHASE1":387,"PHASE1":389,"PHASE2":391,"PHASE3":393,"PHASE4":399,"NA":401},{"trials":388,"activeCount":97},[],{"trials":390,"activeCount":97},[],{"trials":392,"activeCount":97},[],{"trials":394,"activeCount":121,"soonestReadout":369},[395],{"nctId":366,"briefTitle":367,"status":109,"phases":396,"primaryCompletion":369,"completion":370,"start":371,"enrollment":372,"conditions":397,"interventions":398},[87],[374,15,375,376],[355,378,379,380],{"trials":400,"activeCount":97},[],{"trials":402,"activeCount":97},[],{"intervention":379,"totalTrials":121,"cells":404},{"EARLY_PHASE1":405,"PHASE1":407,"PHASE2":409,"PHASE3":411,"PHASE4":417,"NA":419},{"trials":406,"activeCount":97},[],{"trials":408,"activeCount":97},[],{"trials":410,"activeCount":97},[],{"trials":412,"activeCount":121,"soonestReadout":369},[413],{"nctId":366,"briefTitle":367,"status":109,"phases":414,"primaryCompletion":369,"completion":370,"start":371,"enrollment":372,"conditions":415,"interventions":416},[87],[374,15,375,376],[355,378,379,380],{"trials":418,"activeCount":97},[],{"trials":420,"activeCount":97},[],{"intervention":380,"totalTrials":121,"cells":422},{"EARLY_PHASE1":423,"PHASE1":425,"PHASE2":427,"PHASE3":429,"PHASE4":435,"NA":437},{"trials":424,"activeCount":97},[],{"trials":426,"activeCount":97},[],{"trials":428,"activeCount":97},[],{"trials":430,"activeCount":121,"soonestReadout":369},[431],{"nctId":366,"briefTitle":367,"status":109,"phases":432,"primaryCompletion":369,"completion":370,"start":371,"enrollment":372,"conditions":433,"interventions":434},[87],[374,15,375,376],[355,378,379,380],{"trials":436,"activeCount":97},[],{"trials":438,"activeCount":97},[],{"intervention":440,"totalTrials":121,"cells":441},"Wegovy ®",{"EARLY_PHASE1":442,"PHASE1":444,"PHASE2":446,"PHASE3":448,"PHASE4":462,"NA":464},{"trials":443,"activeCount":97},[],{"trials":445,"activeCount":97},[],{"trials":447,"activeCount":97},[],{"trials":449,"activeCount":121,"soonestReadout":454},[450],{"nctId":451,"briefTitle":452,"status":127,"phases":453,"primaryCompletion":454,"completion":455,"start":456,"enrollment":457,"conditions":458,"interventions":461},"NCT07090343","Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement",[87],"2030-09-01","2031-04-01","2026-04-01",826,[459,460],"Aortic Stenosis","Heart Failure",[440],{"trials":463,"activeCount":97},[],{"trials":465,"activeCount":97},[],{"intervention":467,"totalTrials":121,"cells":468},"Olaparib",{"EARLY_PHASE1":469,"PHASE1":471,"PHASE2":473,"PHASE3":475,"PHASE4":492,"NA":494},{"trials":470,"activeCount":97},[],{"trials":472,"activeCount":97},[],{"trials":474,"activeCount":97},[],{"trials":476,"activeCount":121,"soonestReadout":481},[477],{"nctId":478,"briefTitle":479,"status":109,"phases":480,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":485,"interventions":487},"NCT05255653","Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features",[86,87],"2030-01-01","2031-01-01","2021-11-11",1615,[486],"Endometrial Cancer",[467,488,489,490,491],"Chemotherapy","Durvalumab","Medroxyprogesterone Acetate","Megestrol Acetate",{"trials":493,"activeCount":97},[],{"trials":495,"activeCount":97},[],{"intervention":488,"totalTrials":121,"cells":497},{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":502,"PHASE3":504,"PHASE4":510,"NA":512},{"trials":499,"activeCount":97},[],{"trials":501,"activeCount":97},[],{"trials":503,"activeCount":97},[],{"trials":505,"activeCount":121,"soonestReadout":481},[506],{"nctId":478,"briefTitle":479,"status":109,"phases":507,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":508,"interventions":509},[86,87],[486],[467,488,489,490,491],{"trials":511,"activeCount":97},[],{"trials":513,"activeCount":97},[],{"intervention":489,"totalTrials":121,"cells":515},{"EARLY_PHASE1":516,"PHASE1":518,"PHASE2":520,"PHASE3":522,"PHASE4":528,"NA":530},{"trials":517,"activeCount":97},[],{"trials":519,"activeCount":97},[],{"trials":521,"activeCount":97},[],{"trials":523,"activeCount":121,"soonestReadout":481},[524],{"nctId":478,"briefTitle":479,"status":109,"phases":525,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":526,"interventions":527},[86,87],[486],[467,488,489,490,491],{"trials":529,"activeCount":97},[],{"trials":531,"activeCount":97},[],{"intervention":490,"totalTrials":121,"cells":533},{"EARLY_PHASE1":534,"PHASE1":536,"PHASE2":538,"PHASE3":540,"PHASE4":546,"NA":548},{"trials":535,"activeCount":97},[],{"trials":537,"activeCount":97},[],{"trials":539,"activeCount":97},[],{"trials":541,"activeCount":121,"soonestReadout":481},[542],{"nctId":478,"briefTitle":479,"status":109,"phases":543,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":544,"interventions":545},[86,87],[486],[467,488,489,490,491],{"trials":547,"activeCount":97},[],{"trials":549,"activeCount":97},[],{"intervention":491,"totalTrials":121,"cells":551},{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":558,"PHASE4":564,"NA":566},{"trials":553,"activeCount":97},[],{"trials":555,"activeCount":97},[],{"trials":557,"activeCount":97},[],{"trials":559,"activeCount":121,"soonestReadout":481},[560],{"nctId":478,"briefTitle":479,"status":109,"phases":561,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":562,"interventions":563},[86,87],[486],[467,488,489,490,491],{"trials":565,"activeCount":97},[],{"trials":567,"activeCount":97},[],{"intervention":569,"totalTrials":121,"cells":570},"Mifepristone 50 mg",{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":577,"PHASE4":590,"NA":592},{"trials":572,"activeCount":97},[],{"trials":574,"activeCount":97},[],{"trials":576,"activeCount":97},[],{"trials":578,"activeCount":121,"soonestReadout":583},[579],{"nctId":580,"briefTitle":581,"status":109,"phases":582,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":587,"interventions":589},"NCT06394999","Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive",[87],"2029-04","2030-04","2025-05-02",1186,[588],"Female Contraception",[569],{"trials":591,"activeCount":97},[],{"trials":593,"activeCount":97},[],{"intervention":38,"totalTrials":121,"cells":595},{"EARLY_PHASE1":596,"PHASE1":598,"PHASE2":600,"PHASE3":602,"PHASE4":612,"NA":614},{"trials":597,"activeCount":97},[],{"trials":599,"activeCount":97},[],{"trials":601,"activeCount":97},[],{"trials":603,"activeCount":121,"soonestReadout":37},[604],{"nctId":35,"briefTitle":36,"status":605,"phases":606,"primaryCompletion":37,"completion":607,"start":608,"enrollment":318,"conditions":609,"interventions":611},"ACTIVE_NOT_RECRUITING",[87],"2026-06-07","2018-10-01",[610],"Lupus Erythematosus, Systemic",[38],{"trials":613,"activeCount":97},[],{"trials":615,"activeCount":97},[],{"intervention":304,"totalTrials":121,"cells":617},{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":622,"PHASE3":624,"PHASE4":630,"NA":632},{"trials":619,"activeCount":97},[],{"trials":621,"activeCount":97},[],{"trials":623,"activeCount":97},[],{"trials":625,"activeCount":121,"soonestReadout":66},[626],{"nctId":64,"briefTitle":65,"status":109,"phases":627,"primaryCompletion":66,"completion":298,"start":299,"enrollment":300,"conditions":628,"interventions":629},[87],[302],[67,304],{"trials":631,"activeCount":97},[],{"trials":633,"activeCount":97},[],{"intervention":82,"totalTrials":121,"cells":635},{"EARLY_PHASE1":636,"PHASE1":638,"PHASE2":640,"PHASE3":642,"PHASE4":652,"NA":654},{"trials":637,"activeCount":97},[],{"trials":639,"activeCount":97},[],{"trials":641,"activeCount":97},[],{"trials":643,"activeCount":121,"soonestReadout":81},[644],{"nctId":79,"briefTitle":80,"status":109,"phases":645,"primaryCompletion":81,"completion":646,"start":647,"enrollment":648,"conditions":649,"interventions":651},[87],"2027-02-01","2023-10-01",148,[650],"Meniere Disease",[82],{"trials":653,"activeCount":97},[],{"trials":655,"activeCount":97},[],{"intervention":657,"totalTrials":121,"cells":658},"Ipilimumab and nivolumab",{"EARLY_PHASE1":659,"PHASE1":661,"PHASE2":663,"PHASE3":677,"PHASE4":679,"NA":681},{"trials":660,"activeCount":97},[],{"trials":662,"activeCount":97},[],{"trials":664,"activeCount":121,"soonestReadout":669},[665],{"nctId":666,"briefTitle":667,"status":605,"phases":668,"primaryCompletion":669,"completion":670,"start":671,"enrollment":672,"conditions":673,"interventions":675},"NCT04283890","PHP and Immunotherapy in Metastasized UM",[85,86],"2026-12","2029-12","2019-12-04",83,[674],"Uveal Melanoma, Metastatic",[657,676],"Melphalan chemosaturation via percutaneous hepatic perfusion",{"trials":678,"activeCount":97},[],{"trials":680,"activeCount":97},[],{"trials":682,"activeCount":97},[],{"intervention":676,"totalTrials":121,"cells":684},{"EARLY_PHASE1":685,"PHASE1":687,"PHASE2":689,"PHASE3":695,"PHASE4":697,"NA":699},{"trials":686,"activeCount":97},[],{"trials":688,"activeCount":97},[],{"trials":690,"activeCount":121,"soonestReadout":669},[691],{"nctId":666,"briefTitle":667,"status":605,"phases":692,"primaryCompletion":669,"completion":670,"start":671,"enrollment":672,"conditions":693,"interventions":694},[85,86],[674],[657,676],{"trials":696,"activeCount":97},[],{"trials":698,"activeCount":97},[],{"trials":700,"activeCount":97},[],{"intervention":702,"totalTrials":121,"cells":703},"dabrafenib\u002Ftrametinib",{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":708,"PHASE3":721,"PHASE4":723,"NA":725},{"trials":705,"activeCount":97},[],{"trials":707,"activeCount":97},[],{"trials":709,"activeCount":121,"soonestReadout":714},[710],{"nctId":711,"briefTitle":712,"status":109,"phases":713,"primaryCompletion":714,"completion":715,"start":716,"enrollment":717,"conditions":718,"interventions":720},"NCT06079333","NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)",[86],"2027-01-01","2028-01-01","2023-01-01",20,[719],"Anaplastic Thyroid Cancer",[702],{"trials":722,"activeCount":97},[],{"trials":724,"activeCount":97},[],{"trials":726,"activeCount":97},[],{"intervention":728,"totalTrials":121,"cells":729},"Low Sodium Oxybate",{"EARLY_PHASE1":730,"PHASE1":732,"PHASE2":734,"PHASE3":746,"PHASE4":748,"NA":750},{"trials":731,"activeCount":97},[],{"trials":733,"activeCount":97},[],{"trials":735,"activeCount":121,"soonestReadout":740},[736],{"nctId":737,"briefTitle":738,"status":127,"phases":739,"primaryCompletion":740,"completion":741,"start":258,"enrollment":742,"conditions":743,"interventions":745},"NCT06950281","Efficacy, Safety and Tolerability of Low Sodium Oxybate for Nocturnal Cluster Headache Attacks",[86],"2027-12","2028-05",52,[744],"Chronic Cluster Headache",[728],{"trials":747,"activeCount":97},[],{"trials":749,"activeCount":97},[],{"trials":751,"activeCount":97},[],{"intervention":753,"totalTrials":121,"cells":754},"Belimumab Prefilled Syringe [Benlysta]",{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":769,"PHASE4":771,"NA":773},{"trials":756,"activeCount":97},[],{"trials":758,"activeCount":97},[],{"trials":760,"activeCount":121,"soonestReadout":715},[761],{"nctId":762,"briefTitle":763,"status":127,"phases":764,"primaryCompletion":715,"completion":481,"start":456,"enrollment":765,"conditions":766,"interventions":768},"NCT07539857","Belimumab to Mobilise Memory B-cells From Secondary Lymhoid Organs to Improve Memory B-cell HLA-specificity Profiling to Support Delisting for Transplant Access in Highly-sensitized",[86],25,[767],"Kidney Transplant Rejection",[753],{"trials":770,"activeCount":97},[],{"trials":772,"activeCount":97},[],{"trials":774,"activeCount":97},[],{"intervention":776,"totalTrials":121,"cells":777},"XYWAV",{"EARLY_PHASE1":778,"PHASE1":780,"PHASE2":782,"PHASE3":794,"PHASE4":796,"NA":798},{"trials":779,"activeCount":97},[],{"trials":781,"activeCount":97},[],{"trials":783,"activeCount":121,"soonestReadout":789},[784],{"nctId":785,"briefTitle":786,"status":787,"phases":788,"primaryCompletion":789,"completion":789,"start":790,"enrollment":132,"conditions":791,"interventions":793},"NCT06421532","Stimulating Amyloid Clearance in Cerebral Amyloid Angiopathy","ENROLLING_BY_INVITATION",[86],"2027-09-27","2025-03-27",[792],"Cerebral Amyloid Angiopathy",[776],{"trials":795,"activeCount":97},[],{"trials":797,"activeCount":97},[],{"trials":799,"activeCount":97},[],{"intervention":801,"totalTrials":121,"cells":802},"Abiraterone acetate",{"EARLY_PHASE1":803,"PHASE1":805,"PHASE2":807,"PHASE3":820,"PHASE4":822,"NA":824},{"trials":804,"activeCount":97},[],{"trials":806,"activeCount":97},[],{"trials":808,"activeCount":121,"soonestReadout":813},[809],{"nctId":810,"briefTitle":811,"status":109,"phases":812,"primaryCompletion":813,"completion":813,"start":814,"enrollment":815,"conditions":816,"interventions":818},"NCT05393791","Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC",[86],"2027-11-10","2022-11-10",168,[817],"Prostatic Neoplasms, Castration-Resistant",[801,819],"Enzalutamide",{"trials":821,"activeCount":97},[],{"trials":823,"activeCount":97},[],{"trials":825,"activeCount":97},[],{"intervention":819,"totalTrials":121,"cells":827},{"EARLY_PHASE1":828,"PHASE1":830,"PHASE2":832,"PHASE3":838,"PHASE4":840,"NA":842},{"trials":829,"activeCount":97},[],{"trials":831,"activeCount":97},[],{"trials":833,"activeCount":121,"soonestReadout":813},[834],{"nctId":810,"briefTitle":811,"status":109,"phases":835,"primaryCompletion":813,"completion":813,"start":814,"enrollment":815,"conditions":836,"interventions":837},[86],[817],[801,819],{"trials":839,"activeCount":97},[],{"trials":841,"activeCount":97},[],{"trials":843,"activeCount":97},[],{"intervention":58,"totalTrials":121,"cells":845},{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":857,"PHASE3":859,"PHASE4":861,"NA":863},{"trials":847,"activeCount":97},[],{"trials":849,"activeCount":121,"soonestReadout":57},[850],{"nctId":55,"briefTitle":56,"status":127,"phases":851,"primaryCompletion":57,"completion":852,"start":131,"enrollment":853,"conditions":854,"interventions":856},[85],"2025-09-30",14,[855],"Malaria,Falciparum",[58],{"trials":858,"activeCount":97},[],{"trials":860,"activeCount":97},[],{"trials":862,"activeCount":97},[],{"trials":864,"activeCount":97},[],{"intervention":48,"totalTrials":121,"cells":866},{"EARLY_PHASE1":867,"PHASE1":869,"PHASE2":881,"PHASE3":883,"PHASE4":885,"NA":887},{"trials":868,"activeCount":97},[],{"trials":870,"activeCount":121,"soonestReadout":47},[871],{"nctId":45,"briefTitle":46,"status":109,"phases":872,"primaryCompletion":47,"completion":47,"start":873,"enrollment":874,"conditions":875,"interventions":878},[85],"2024-10-10",85,[876,877],"Shigellosis","Bacillary Dysentery",[48,879,880],"10 μg InvaplexAR-Detox","0.1 μg of dmLT",{"trials":882,"activeCount":97},[],{"trials":884,"activeCount":97},[],{"trials":886,"activeCount":97},[],{"trials":888,"activeCount":97},[],{"intervention":879,"totalTrials":121,"cells":890},{"EARLY_PHASE1":891,"PHASE1":893,"PHASE2":899,"PHASE3":901,"PHASE4":903,"NA":905},{"trials":892,"activeCount":97},[],{"trials":894,"activeCount":121,"soonestReadout":47},[895],{"nctId":45,"briefTitle":46,"status":109,"phases":896,"primaryCompletion":47,"completion":47,"start":873,"enrollment":874,"conditions":897,"interventions":898},[85],[876,877],[48,879,880],{"trials":900,"activeCount":97},[],{"trials":902,"activeCount":97},[],{"trials":904,"activeCount":97},[],{"trials":906,"activeCount":97},[],{"intervention":880,"totalTrials":121,"cells":908},{"EARLY_PHASE1":909,"PHASE1":911,"PHASE2":917,"PHASE3":919,"PHASE4":921,"NA":923},{"trials":910,"activeCount":97},[],{"trials":912,"activeCount":121,"soonestReadout":47},[913],{"nctId":45,"briefTitle":46,"status":109,"phases":914,"primaryCompletion":47,"completion":47,"start":873,"enrollment":874,"conditions":915,"interventions":916},[85],[876,877],[48,879,880],{"trials":918,"activeCount":97},[],{"trials":920,"activeCount":97},[],{"trials":922,"activeCount":97},[],{"trials":924,"activeCount":97},[],{"intervention":926,"totalTrials":121,"cells":927},"Narcan 40 MG\u002FML Nasal Spray",{"EARLY_PHASE1":928,"PHASE1":930,"PHASE2":946,"PHASE3":948,"PHASE4":950,"NA":952},{"trials":929,"activeCount":97},[],{"trials":931,"activeCount":121,"soonestReadout":936},[932],{"nctId":933,"briefTitle":934,"status":109,"phases":935,"primaryCompletion":936,"completion":937,"start":938,"enrollment":939,"conditions":940,"interventions":943},"NCT05338632","Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists",[85],"2026-08-01","2026-10-01","2022-06-24",24,[941,942],"Opioid Induced Respiratory Depression","Chronic Opioid Use",[926,944,945],"Naloxone Hydrochloride","Nalmefene HCl",{"trials":947,"activeCount":97},[],{"trials":949,"activeCount":97},[],{"trials":951,"activeCount":97},[],{"trials":953,"activeCount":97},[],{"intervention":944,"totalTrials":121,"cells":955},{"EARLY_PHASE1":956,"PHASE1":958,"PHASE2":964,"PHASE3":966,"PHASE4":968,"NA":970},{"trials":957,"activeCount":97},[],{"trials":959,"activeCount":121,"soonestReadout":936},[960],{"nctId":933,"briefTitle":934,"status":109,"phases":961,"primaryCompletion":936,"completion":937,"start":938,"enrollment":939,"conditions":962,"interventions":963},[85],[941,942],[926,944,945],{"trials":965,"activeCount":97},[],{"trials":967,"activeCount":97},[],{"trials":969,"activeCount":97},[],{"trials":971,"activeCount":97},[],{"intervention":945,"totalTrials":121,"cells":973},{"EARLY_PHASE1":974,"PHASE1":976,"PHASE2":982,"PHASE3":984,"PHASE4":986,"NA":988},{"trials":975,"activeCount":97},[],{"trials":977,"activeCount":121,"soonestReadout":936},[978],{"nctId":933,"briefTitle":934,"status":109,"phases":979,"primaryCompletion":936,"completion":937,"start":938,"enrollment":939,"conditions":980,"interventions":981},[85],[941,942],[926,944,945],{"trials":983,"activeCount":97},[],{"trials":985,"activeCount":97},[],{"trials":987,"activeCount":97},[],{"trials":989,"activeCount":97},[],{"intervention":138,"totalTrials":286,"cells":991},{"EARLY_PHASE1":992,"PHASE1":994,"PHASE2":1009,"PHASE3":1011,"PHASE4":1013,"NA":1029},{"trials":993,"activeCount":97},[],{"trials":995,"activeCount":97},[996],{"nctId":997,"briefTitle":998,"status":153,"phases":999,"primaryCompletion":1000,"completion":1001,"start":1002,"enrollment":318,"conditions":1003,"interventions":1005},"NCT05693077","Clostridioides Difficile Colonisation",[85],"2024-06","2025-06","2023-09-22",[1004],"Clostridioides Difficile Infection",[1006,1007,1008],"10E4 NTCD spores","10E7 NTCD spores","Vancomycin Oral",{"trials":1010,"activeCount":97},[],{"trials":1012,"activeCount":97},[],{"trials":1014,"activeCount":97},[1015],{"nctId":1016,"briefTitle":1017,"status":1018,"phases":1019,"primaryCompletion":1020,"completion":1021,"start":1022,"enrollment":97,"conditions":1023,"interventions":1027},"NCT05077085","Bezlotoxumab Versus FMT for Multiple Recurrent CDI","WITHDRAWN",[88],"2024-07","2024-12","2022-01",[1024,1025,1026],"Clostridium Infections","Clostridioides Difficile","Enterocolitis, Pseudomembranous",[1028,138],"Bezlotoxumab",{"trials":1030,"activeCount":121,"soonestReadout":129},[1031],{"nctId":125,"briefTitle":126,"status":127,"phases":1032,"primaryCompletion":129,"completion":130,"start":131,"enrollment":132,"conditions":1033,"interventions":1034},[89],[134,135,136],[138,92],{"intervention":43,"totalTrials":93,"cells":1036},{"EARLY_PHASE1":1037,"PHASE1":1039,"PHASE2":1041,"PHASE3":1043,"PHASE4":1045,"NA":1047},{"trials":1038,"activeCount":97},[],{"trials":1040,"activeCount":97},[],{"trials":1042,"activeCount":97},[],{"trials":1044,"activeCount":97},[],{"trials":1046,"activeCount":97},[],{"trials":1048,"activeCount":121,"soonestReadout":42},[1049,1056],{"nctId":40,"briefTitle":41,"status":127,"phases":1050,"primaryCompletion":42,"completion":1051,"start":1052,"enrollment":21,"conditions":1053,"interventions":1055},[89],"2026-10","2024-10-01",[1054],"Necator Americanus Infection",[43],{"nctId":1057,"briefTitle":1058,"status":314,"phases":1059,"primaryCompletion":1060,"completion":1061,"start":1062,"enrollment":28,"conditions":1063,"interventions":1064},"NCT03126552","Establishing a Controlled Human Hookworm Infection Model at Leiden University Medical Center",[89],"2017-08-15","2021-11-22","2017-04-01",[1054],[43],{"intervention":72,"totalTrials":121,"cells":1066},{"EARLY_PHASE1":1067,"PHASE1":1069,"PHASE2":1071,"PHASE3":1073,"PHASE4":1075,"NA":1077},{"trials":1068,"activeCount":97},[],{"trials":1070,"activeCount":97},[],{"trials":1072,"activeCount":97},[],{"trials":1074,"activeCount":97},[],{"trials":1076,"activeCount":97},[],{"trials":1078,"activeCount":121,"soonestReadout":71},[1079],{"nctId":69,"briefTitle":70,"status":605,"phases":1080,"primaryCompletion":71,"completion":1051,"start":1081,"enrollment":1082,"conditions":1083,"interventions":1085},[],"2022-12-01",2000,[1084],"Adverse Drug Reaction",[72],{"intervention":1087,"totalTrials":121,"cells":1088},"SGLT2 inhibitors",{"EARLY_PHASE1":1089,"PHASE1":1091,"PHASE2":1093,"PHASE3":1095,"PHASE4":1097,"NA":1099},{"trials":1090,"activeCount":97},[],{"trials":1092,"activeCount":97},[],{"trials":1094,"activeCount":97},[],{"trials":1096,"activeCount":97},[],{"trials":1098,"activeCount":97},[],{"trials":1100,"activeCount":121,"soonestReadout":1105},[1101],{"nctId":1102,"briefTitle":1103,"status":109,"phases":1104,"primaryCompletion":1105,"completion":1105,"start":716,"enrollment":1106,"conditions":1107,"interventions":1116},"NCT06932081","Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry",[],"2027-12-31",400,[1108,1109,1110,1111,1112,1113,1114,1115],"Adult Congenital Heart Disease","Congenital Heart Disease","Systemic Right Ventricle","Transposition of the Great Arteries","Congenitally Corrected Transposition of the Great Arteries","Fontan","Single Ventricle","Tetralogy of Fallot (TOF)",[1087],{"intervention":1118,"totalTrials":121,"cells":1119},"doxycycline 200 mg q.d. - rifampicin 600mg b.i.d.",{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1126,"PHASE4":1128,"NA":1130},{"trials":1121,"activeCount":97},[],{"trials":1123,"activeCount":97},[],{"trials":1125,"activeCount":97},[],{"trials":1127,"activeCount":97},[],{"trials":1129,"activeCount":97},[],{"trials":1131,"activeCount":121,"soonestReadout":1136},[1132],{"nctId":1133,"briefTitle":1134,"status":109,"phases":1135,"primaryCompletion":1136,"completion":1136,"start":1137,"enrollment":1138,"conditions":1139,"interventions":1141},"NCT05268120","MRSA Decolonization in Complicated Carriage",[89],"2028-05-01","2022-07-25",211,[1140],"MRSA",[1118,1142],"trimethoprim 200mg b.i.d. - rifampicin 600mg b.i.d.",{"intervention":1142,"totalTrials":121,"cells":1144},{"EARLY_PHASE1":1145,"PHASE1":1147,"PHASE2":1149,"PHASE3":1151,"PHASE4":1153,"NA":1155},{"trials":1146,"activeCount":97},[],{"trials":1148,"activeCount":97},[],{"trials":1150,"activeCount":97},[],{"trials":1152,"activeCount":97},[],{"trials":1154,"activeCount":97},[],{"trials":1156,"activeCount":121,"soonestReadout":1136},[1157],{"nctId":1133,"briefTitle":1134,"status":109,"phases":1158,"primaryCompletion":1136,"completion":1136,"start":1137,"enrollment":1138,"conditions":1159,"interventions":1160},[89],[1140],[1118,1142],{"intervention":1162,"totalTrials":121,"cells":1163},"Gene therapy",{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1168,"PHASE3":1170,"PHASE4":1172,"NA":1174},{"trials":1165,"activeCount":97},[],{"trials":1167,"activeCount":97},[],{"trials":1169,"activeCount":97},[],{"trials":1171,"activeCount":97},[],{"trials":1173,"activeCount":97},[],{"trials":1175,"activeCount":121,"soonestReadout":1180},[1176],{"nctId":1177,"briefTitle":1178,"status":109,"phases":1179,"primaryCompletion":1180,"completion":1180,"start":1181,"enrollment":1182,"conditions":1183,"interventions":1185},"NCT04797260","Phase I\u002FII Clinical Trial Stem Cell Gene Therapy in RAG1-Deficient SCID",[89],"2029-12-31","2021-07-23",10,[1184],"Severe Combined Immunodeficiency Due to RAG1 Deficiency",[1162],{"intervention":1187,"totalTrials":121,"cells":1188},"thrombolysis therapy",{"EARLY_PHASE1":1189,"PHASE1":1191,"PHASE2":1193,"PHASE3":1195,"PHASE4":1197,"NA":1199},{"trials":1190,"activeCount":97},[],{"trials":1192,"activeCount":97},[],{"trials":1194,"activeCount":97},[],{"trials":1196,"activeCount":97},[],{"trials":1198,"activeCount":97},[],{"trials":1200,"activeCount":121,"soonestReadout":340},[1201],{"nctId":1202,"briefTitle":1203,"status":109,"phases":1204,"primaryCompletion":340,"completion":341,"start":1205,"enrollment":1206,"conditions":1207,"interventions":1209},"NCT06833827","'Thrombectomy in High-Risk Pulmonary Embolism - Device Versus Thrombolysis Netherlands': TORPEDO-NL",[89],"2025-02",111,[1208],"Pulmonary Embolism Acute",[1187],{"intervention":77,"totalTrials":121,"cells":1211},{"EARLY_PHASE1":1212,"PHASE1":1214,"PHASE2":1216,"PHASE3":1218,"PHASE4":1220,"NA":1222},{"trials":1213,"activeCount":97},[],{"trials":1215,"activeCount":97},[],{"trials":1217,"activeCount":97},[],{"trials":1219,"activeCount":97},[],{"trials":1221,"activeCount":97},[],{"trials":1223,"activeCount":121,"soonestReadout":76},[1224],{"nctId":74,"briefTitle":75,"status":109,"phases":1225,"primaryCompletion":76,"completion":76,"start":1226,"enrollment":1227,"conditions":1228,"interventions":1229},[],"2022-08-16",180,[221],[77],{"intervention":62,"totalTrials":121,"cells":1231},{"EARLY_PHASE1":1232,"PHASE1":1234,"PHASE2":1236,"PHASE3":1238,"PHASE4":1240,"NA":1242},{"trials":1233,"activeCount":97},[],{"trials":1235,"activeCount":97},[],{"trials":1237,"activeCount":97},[],{"trials":1239,"activeCount":97},[],{"trials":1241,"activeCount":97},[],{"trials":1243,"activeCount":121,"soonestReadout":57},[1244],{"nctId":60,"briefTitle":61,"status":109,"phases":1245,"primaryCompletion":57,"completion":1246,"start":1247,"enrollment":1248,"conditions":1249,"interventions":1252},[89],"2026-12-01","2022-05-02",30,[1250,1251],"Uterine Cervical Neoplasms","Locally Advanced Cervical Carcinoma",[62],{"intervention":1254,"totalTrials":93,"cells":1255},"Tacrolimus",{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1260,"PHASE3":1274,"PHASE4":1276,"NA":1290},{"trials":1257,"activeCount":97},[],{"trials":1259,"activeCount":97},[],{"trials":1261,"activeCount":97},[1262],{"nctId":1263,"briefTitle":1264,"status":314,"phases":1265,"primaryCompletion":1266,"completion":1267,"start":1268,"enrollment":717,"conditions":1269,"interventions":1272},"NCT04701528","Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients",[86],"2022-03-25","2022-10-25","2020-11-15",[1270,1271],"Covid19","Kidney Transplant Infection",[1273,1254],"Voclosporin",{"trials":1275,"activeCount":97},[],{"trials":1277,"activeCount":97},[1278],{"nctId":1279,"briefTitle":1280,"status":153,"phases":1281,"primaryCompletion":1282,"completion":1283,"start":1284,"enrollment":1285,"conditions":1286,"interventions":1288},"NCT05221411","Tacrolimus Versus Mycophenolate for Autoimmune Hepatitis Patients With Incomplete Response on First Line Therapy",[88],"2023-01","2024-01","2022-01-19",86,[1287],"Autoimmune Hepatitis",[1289,1254],"Mycophenolate Mofetil",{"trials":1291,"activeCount":97},[],{"intervention":1293,"totalTrials":93,"cells":1294},"Sugammadex",{"EARLY_PHASE1":1295,"PHASE1":1297,"PHASE2":1299,"PHASE3":1301,"PHASE4":1303,"NA":1325},{"trials":1296,"activeCount":97},[],{"trials":1298,"activeCount":97},[],{"trials":1300,"activeCount":97},[],{"trials":1302,"activeCount":97},[],{"trials":1304,"activeCount":97},[1305,1316],{"nctId":1306,"briefTitle":1307,"status":314,"phases":1308,"primaryCompletion":1309,"completion":1309,"start":1310,"enrollment":1311,"conditions":1312,"interventions":1314},"NCT02845375","Effect of Neuromuscular Blockade and Reversal on Breathing",[88],"2018-09-01","2016-09-01",46,[1313],"Respiratory Insufficiency",[1293,1315],"Neostigmine",{"nctId":1317,"briefTitle":1318,"status":314,"phases":1319,"primaryCompletion":1320,"completion":1320,"start":1321,"enrollment":157,"conditions":1322,"interventions":1324},"NCT02243943","Effect of Neuromuscular Reversal With Sugammadex on Postoperative Recovery Profile",[88],"2016-04","2014-09",[1323],"Postoperative Respiratory Condition",[1293,1315],{"trials":1326,"activeCount":97},[],{"intervention":1315,"totalTrials":93,"cells":1328},{"EARLY_PHASE1":1329,"PHASE1":1331,"PHASE2":1333,"PHASE3":1335,"PHASE4":1337,"NA":1347},{"trials":1330,"activeCount":97},[],{"trials":1332,"activeCount":97},[],{"trials":1334,"activeCount":97},[],{"trials":1336,"activeCount":97},[],{"trials":1338,"activeCount":97},[1339,1343],{"nctId":1306,"briefTitle":1307,"status":314,"phases":1340,"primaryCompletion":1309,"completion":1309,"start":1310,"enrollment":1311,"conditions":1341,"interventions":1342},[88],[1313],[1293,1315],{"nctId":1317,"briefTitle":1318,"status":314,"phases":1344,"primaryCompletion":1320,"completion":1320,"start":1321,"enrollment":157,"conditions":1345,"interventions":1346},[88],[1323],[1293,1315],{"trials":1348,"activeCount":97},[],{"intervention":1350,"totalTrials":93,"cells":1351},"Liraglutide",{"EARLY_PHASE1":1352,"PHASE1":1354,"PHASE2":1356,"PHASE3":1358,"PHASE4":1360,"NA":1385},{"trials":1353,"activeCount":97},[],{"trials":1355,"activeCount":97},[],{"trials":1357,"activeCount":97},[],{"trials":1359,"activeCount":97},[],{"trials":1361,"activeCount":97},[1362,1376],{"nctId":1363,"briefTitle":1364,"status":314,"phases":1365,"primaryCompletion":1366,"completion":1366,"start":1367,"enrollment":300,"conditions":1368,"interventions":1374},"NCT01761318","Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients",[88],"2016-03","2013-11",[1369,1370,1371,1372,1373],"Diabetes Mellitus Type 2","Metabolic Syndrome","Cardiovascular Disease","Diastolic Dysfunction","Fatty Liver",[1350,1375],"Liraglutide - Placebo",{"nctId":1377,"briefTitle":1378,"status":314,"phases":1379,"primaryCompletion":1380,"completion":1380,"start":1381,"enrollment":1382,"conditions":1383,"interventions":1384},"NCT02660047","Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent",[88],"2018-03-09","2015-08",51,[1369,1370,1371,1372,1373],[1350,1375],{"trials":1386,"activeCount":97},[],{"intervention":1375,"totalTrials":93,"cells":1388},{"EARLY_PHASE1":1389,"PHASE1":1391,"PHASE2":1393,"PHASE3":1395,"PHASE4":1397,"NA":1407},{"trials":1390,"activeCount":97},[],{"trials":1392,"activeCount":97},[],{"trials":1394,"activeCount":97},[],{"trials":1396,"activeCount":97},[],{"trials":1398,"activeCount":97},[1399,1403],{"nctId":1363,"briefTitle":1364,"status":314,"phases":1400,"primaryCompletion":1366,"completion":1366,"start":1367,"enrollment":300,"conditions":1401,"interventions":1402},[88],[1369,1370,1371,1372,1373],[1350,1375],{"nctId":1377,"briefTitle":1378,"status":314,"phases":1404,"primaryCompletion":1380,"completion":1380,"start":1381,"enrollment":1382,"conditions":1405,"interventions":1406},[88],[1369,1370,1371,1372,1373],[1350,1375],{"trials":1408,"activeCount":97},[],{"intervention":1410,"totalTrials":93,"cells":1411},"Methotrexate",{"EARLY_PHASE1":1412,"PHASE1":1414,"PHASE2":1416,"PHASE3":1430,"PHASE4":1432,"NA":1446},{"trials":1413,"activeCount":97},[],{"trials":1415,"activeCount":97},[],{"trials":1417,"activeCount":97},[1418],{"nctId":1419,"briefTitle":1420,"status":153,"phases":1421,"start":1422,"conditions":1423,"interventions":1424},"NCT00002498","Combination Chemotherapy Compared With Mitoxantrone in Treating Older Patients With Advanced Breast Cancer",[86],"1992-07",[23],[1425,1426,1427,1428,1429],"CMF regimen","cyclophosphamide","fluorouracil","methotrexate","mitoxantrone hydrochloride",{"trials":1431,"activeCount":97},[],{"trials":1433,"activeCount":97},[1434],{"nctId":1435,"briefTitle":1436,"status":314,"phases":1437,"primaryCompletion":1438,"completion":1439,"start":1440,"enrollment":1311,"conditions":1441,"interventions":1444},"NCT03492658","Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA)",[88],"2021-10-26","2022-04-06","2018-05-17",[1442,1443],"Rheumatoid Arthritis","Rheumatic Diseases",[1445,1410],"Abatacept",{"trials":1447,"activeCount":97},[],{"intervention":1289,"totalTrials":121,"cells":1449},{"EARLY_PHASE1":1450,"PHASE1":1452,"PHASE2":1454,"PHASE3":1456,"PHASE4":1458,"NA":1464},{"trials":1451,"activeCount":97},[],{"trials":1453,"activeCount":97},[],{"trials":1455,"activeCount":97},[],{"trials":1457,"activeCount":97},[],{"trials":1459,"activeCount":97},[1460],{"nctId":1279,"briefTitle":1280,"status":153,"phases":1461,"primaryCompletion":1282,"completion":1283,"start":1284,"enrollment":1285,"conditions":1462,"interventions":1463},[88],[1287],[1289,1254],{"trials":1465,"activeCount":97},[],{"intervention":1467,"totalTrials":121,"cells":1468},"Pregabalin 150mg",{"EARLY_PHASE1":1469,"PHASE1":1471,"PHASE2":1473,"PHASE3":1475,"PHASE4":1477,"NA":1490},{"trials":1470,"activeCount":97},[],{"trials":1472,"activeCount":97},[],{"trials":1474,"activeCount":97},[],{"trials":1476,"activeCount":97},[],{"trials":1478,"activeCount":97},[1479],{"nctId":1480,"briefTitle":1481,"status":314,"phases":1482,"primaryCompletion":1483,"completion":1483,"start":1484,"enrollment":939,"conditions":1485,"interventions":1487},"NCT05598905","Combined Effect of Pregabalin and Oxycodone, and Lacosamide and Oxycodone, on Breathing",[88],"2024-01-12","2022-10-10",[1486],"Opioid-induced Respiratory Depression",[1467,1488,1489],"Oxycodone 10mg","Lacosamide 150 mg",{"trials":1491,"activeCount":97},[],{"intervention":1488,"totalTrials":121,"cells":1493},{"EARLY_PHASE1":1494,"PHASE1":1496,"PHASE2":1498,"PHASE3":1500,"PHASE4":1502,"NA":1508},{"trials":1495,"activeCount":97},[],{"trials":1497,"activeCount":97},[],{"trials":1499,"activeCount":97},[],{"trials":1501,"activeCount":97},[],{"trials":1503,"activeCount":97},[1504],{"nctId":1480,"briefTitle":1481,"status":314,"phases":1505,"primaryCompletion":1483,"completion":1483,"start":1484,"enrollment":939,"conditions":1506,"interventions":1507},[88],[1486],[1467,1488,1489],{"trials":1509,"activeCount":97},[],{"intervention":1489,"totalTrials":121,"cells":1511},{"EARLY_PHASE1":1512,"PHASE1":1514,"PHASE2":1516,"PHASE3":1518,"PHASE4":1520,"NA":1526},{"trials":1513,"activeCount":97},[],{"trials":1515,"activeCount":97},[],{"trials":1517,"activeCount":97},[],{"trials":1519,"activeCount":97},[],{"trials":1521,"activeCount":97},[1522],{"nctId":1480,"briefTitle":1481,"status":314,"phases":1523,"primaryCompletion":1483,"completion":1483,"start":1484,"enrollment":939,"conditions":1524,"interventions":1525},[88],[1486],[1467,1488,1489],{"trials":1527,"activeCount":97},[],{"intervention":1529,"totalTrials":121,"cells":1530},"short treatment",{"EARLY_PHASE1":1531,"PHASE1":1533,"PHASE2":1535,"PHASE3":1537,"PHASE4":1539,"NA":1552},{"trials":1532,"activeCount":97},[],{"trials":1534,"activeCount":97},[],{"trials":1536,"activeCount":97},[],{"trials":1538,"activeCount":97},[],{"trials":1540,"activeCount":97},[1541],{"nctId":1542,"briefTitle":1543,"status":314,"phases":1544,"primaryCompletion":1545,"completion":1546,"start":1547,"enrollment":1548,"conditions":1549,"interventions":1551},"NCT00809913","Febrile Urinary Tract Infection Randomized Short Treatment Trial",[88],"2013-05","2013-09","2008-12",200,[1550],"Urinary Tract Infection",[1529],{"trials":1553,"activeCount":97},[],{"intervention":1555,"totalTrials":121,"cells":1556},"Filgotinib",{"EARLY_PHASE1":1557,"PHASE1":1559,"PHASE2":1561,"PHASE3":1563,"PHASE4":1565,"NA":1578},{"trials":1558,"activeCount":97},[],{"trials":1560,"activeCount":97},[],{"trials":1562,"activeCount":97},[],{"trials":1564,"activeCount":97},[],{"trials":1566,"activeCount":97},[1567],{"nctId":1568,"briefTitle":1569,"status":153,"phases":1570,"primaryCompletion":1571,"completion":1572,"start":1573,"enrollment":1574,"conditions":1575,"interventions":1576},"NCT05502731","Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis",[88],"2025-03","2025-10","2022-10",40,[1442],[1555,1577],"Adalimumab",{"trials":1579,"activeCount":97},[],{"intervention":1577,"totalTrials":121,"cells":1581},{"EARLY_PHASE1":1582,"PHASE1":1584,"PHASE2":1586,"PHASE3":1588,"PHASE4":1590,"NA":1596},{"trials":1583,"activeCount":97},[],{"trials":1585,"activeCount":97},[],{"trials":1587,"activeCount":97},[],{"trials":1589,"activeCount":97},[],{"trials":1591,"activeCount":97},[1592],{"nctId":1568,"briefTitle":1569,"status":153,"phases":1593,"primaryCompletion":1571,"completion":1572,"start":1573,"enrollment":1574,"conditions":1594,"interventions":1595},[88],[1442],[1555,1577],{"trials":1597,"activeCount":97},[],{"intervention":1599,"totalTrials":121,"cells":1600},"Sodium zirconium cyclosilicate",{"EARLY_PHASE1":1601,"PHASE1":1603,"PHASE2":1605,"PHASE3":1607,"PHASE4":1609,"NA":1624},{"trials":1602,"activeCount":97},[],{"trials":1604,"activeCount":97},[],{"trials":1606,"activeCount":97},[],{"trials":1608,"activeCount":97},[],{"trials":1610,"activeCount":97},[1611],{"nctId":1612,"briefTitle":1613,"status":153,"phases":1614,"primaryCompletion":1615,"completion":1615,"start":1616,"enrollment":1617,"conditions":1618,"interventions":1623},"NCT06365684","Sodium Zirconium Cyclosilicate to Allow Liberal Fruit and Vegetable Intake for Patients With CKD Stage 3b and 4",[88],"2025-05-01","2024-04-29",16,[1619,1620,1621,1622],"Hyperkalemia","Diet Modification","Chronic Kidney Disease","Sodium Zirconium Cyclosilicate",[1599],{"trials":1625,"activeCount":97},[],{"intervention":1627,"totalTrials":121,"cells":1628},"Dopamine Agonists",{"EARLY_PHASE1":1629,"PHASE1":1631,"PHASE2":1633,"PHASE3":1635,"PHASE4":1637,"NA":1650},{"trials":1630,"activeCount":97},[],{"trials":1632,"activeCount":97},[],{"trials":1634,"activeCount":97},[],{"trials":1636,"activeCount":97},[],{"trials":1638,"activeCount":97},[1639],{"nctId":1640,"briefTitle":1641,"status":153,"phases":1642,"primaryCompletion":1643,"completion":76,"start":1644,"enrollment":1645,"conditions":1646,"interventions":1649},"NCT04107480","PRolaCT - Three Prolactinoma RCTs",[88],"2024-03-31","2019-06-21",880,[1647,1648],"Prolactinoma","Prolactin-Producing Pituitary Tumor",[1627],{"trials":1651,"activeCount":97},[],{"intervention":1653,"totalTrials":121,"cells":1654},"Medicinal cannabis in combination with oxycodon",{"EARLY_PHASE1":1655,"PHASE1":1657,"PHASE2":1659,"PHASE3":1661,"PHASE4":1663,"NA":1678},{"trials":1656,"activeCount":97},[],{"trials":1658,"activeCount":97},[],{"trials":1660,"activeCount":97},[],{"trials":1662,"activeCount":97},[],{"trials":1664,"activeCount":97},[1665],{"nctId":1666,"briefTitle":1667,"status":153,"phases":1668,"primaryCompletion":1669,"completion":1670,"start":1671,"enrollment":717,"conditions":1672,"interventions":1676},"NCT05235503","Influence of Δ9-tetrahydrocannabinol (THC) on Oxycodone Induced Ventilatory Depression in Healthy Volunteers",[88],"2022-12","2023-06","2021-12-09",[1673,1674,1675],"Respiratory Depression","Cannabis Use","Opioid Use",[1653,1677],"Medicinal cannabis in combination with placebo oxycodon",{"trials":1679,"activeCount":97},[],{"intervention":1677,"totalTrials":121,"cells":1681},{"EARLY_PHASE1":1682,"PHASE1":1684,"PHASE2":1686,"PHASE3":1688,"PHASE4":1690,"NA":1696},{"trials":1683,"activeCount":97},[],{"trials":1685,"activeCount":97},[],{"trials":1687,"activeCount":97},[],{"trials":1689,"activeCount":97},[],{"trials":1691,"activeCount":97},[1692],{"nctId":1666,"briefTitle":1667,"status":153,"phases":1693,"primaryCompletion":1669,"completion":1670,"start":1671,"enrollment":717,"conditions":1694,"interventions":1695},[88],[1673,1674,1675],[1653,1677],{"trials":1697,"activeCount":97},[],{"intervention":1699,"totalTrials":121,"cells":1700},"Epoetin beta",{"EARLY_PHASE1":1701,"PHASE1":1703,"PHASE2":1705,"PHASE3":1707,"PHASE4":1709,"NA":1722},{"trials":1702,"activeCount":97},[],{"trials":1704,"activeCount":97},[],{"trials":1706,"activeCount":97},[],{"trials":1708,"activeCount":97},[],{"trials":1710,"activeCount":97},[1711],{"nctId":1712,"briefTitle":1713,"status":314,"phases":1714,"primaryCompletion":1715,"completion":1716,"start":1717,"enrollment":1718,"conditions":1719,"interventions":1721},"NCT00157300","PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation",[88],"2010-03","2010-07","2005-07",92,[1720],"Patients Receiving a Kidney From a Non-Heart-Beating Donor",[1699],{"trials":1723,"activeCount":97},[],{"intervention":1028,"totalTrials":121,"cells":1725},{"EARLY_PHASE1":1726,"PHASE1":1728,"PHASE2":1730,"PHASE3":1732,"PHASE4":1734,"NA":1740},{"trials":1727,"activeCount":97},[],{"trials":1729,"activeCount":97},[],{"trials":1731,"activeCount":97},[],{"trials":1733,"activeCount":97},[],{"trials":1735,"activeCount":97},[1736],{"nctId":1016,"briefTitle":1017,"status":1018,"phases":1737,"primaryCompletion":1020,"completion":1021,"start":1022,"enrollment":97,"conditions":1738,"interventions":1739},[88],[1024,1025,1026],[1028,138],{"trials":1741,"activeCount":97},[],{"intervention":1743,"totalTrials":121,"cells":1744},"Surgical block",{"EARLY_PHASE1":1745,"PHASE1":1747,"PHASE2":1749,"PHASE3":1751,"PHASE4":1753,"NA":1765},{"trials":1746,"activeCount":97},[],{"trials":1748,"activeCount":97},[],{"trials":1750,"activeCount":97},[],{"trials":1752,"activeCount":97},[],{"trials":1754,"activeCount":97},[1755],{"nctId":1756,"briefTitle":1757,"status":314,"phases":1758,"primaryCompletion":1759,"completion":1759,"start":1760,"enrollment":939,"conditions":1761,"interventions":1764},"NCT01631149","Effect of Deep BLock on Intraoperative Surgical Conditions",[88],"2013-03","2012-06",[1762,1763],"Prostate Hypertrophy","Renal Disease",[1743,1743],{"trials":1766,"activeCount":97},[],{"intervention":1768,"totalTrials":121,"cells":1769},"Eplerenone",{"EARLY_PHASE1":1770,"PHASE1":1772,"PHASE2":1774,"PHASE3":1776,"PHASE4":1778,"NA":1791},{"trials":1771,"activeCount":97},[],{"trials":1773,"activeCount":97},[],{"trials":1775,"activeCount":97},[],{"trials":1777,"activeCount":97},[],{"trials":1779,"activeCount":97},[1780],{"nctId":1781,"briefTitle":1782,"status":153,"phases":1783,"primaryCompletion":1784,"completion":1785,"start":1786,"enrollment":1787,"conditions":1788,"interventions":1790},"NCT03079141","Photodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous Chorioretinopathy",[88],"2019-08-28","2021-08","2017-02-20",107,[1789],"Chronic Central Serous Chorioretinopathy",[1768],{"trials":1792,"activeCount":97},[],{"intervention":1794,"totalTrials":121,"cells":1795},"Intravenous iron",{"EARLY_PHASE1":1796,"PHASE1":1798,"PHASE2":1800,"PHASE3":1802,"PHASE4":1804,"NA":1820},{"trials":1797,"activeCount":97},[],{"trials":1799,"activeCount":97},[],{"trials":1801,"activeCount":97},[],{"trials":1803,"activeCount":97},[],{"trials":1805,"activeCount":97},[1806],{"nctId":1807,"briefTitle":1808,"status":153,"phases":1809,"primaryCompletion":1810,"completion":1810,"start":1811,"enrollment":1812,"conditions":1813,"interventions":1817},"NCT05456932","Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease",[88],"2023-08-31","2022-08-19",90,[1814,1815,1816],"Inflammatory Bowel Diseases","Iron-deficiency","Iron Deficiency Anemia",[1794,1818,1819],"Ferric maltol","Ferrous fumarate",{"trials":1821,"activeCount":97},[],{"intervention":1818,"totalTrials":121,"cells":1823},{"EARLY_PHASE1":1824,"PHASE1":1826,"PHASE2":1828,"PHASE3":1830,"PHASE4":1832,"NA":1838},{"trials":1825,"activeCount":97},[],{"trials":1827,"activeCount":97},[],{"trials":1829,"activeCount":97},[],{"trials":1831,"activeCount":97},[],{"trials":1833,"activeCount":97},[1834],{"nctId":1807,"briefTitle":1808,"status":153,"phases":1835,"primaryCompletion":1810,"completion":1810,"start":1811,"enrollment":1812,"conditions":1836,"interventions":1837},[88],[1814,1815,1816],[1794,1818,1819],{"trials":1839,"activeCount":97},[],{"intervention":1841,"totalTrials":121,"cells":1842},"Dukoral",{"EARLY_PHASE1":1843,"PHASE1":1845,"PHASE2":1847,"PHASE3":1849,"PHASE4":1851,"NA":1863},{"trials":1844,"activeCount":97},[],{"trials":1846,"activeCount":97},[],{"trials":1848,"activeCount":97},[],{"trials":1850,"activeCount":97},[],{"trials":1852,"activeCount":97},[1853],{"nctId":1854,"briefTitle":1855,"status":314,"phases":1856,"primaryCompletion":1857,"completion":1857,"start":1858,"enrollment":1382,"conditions":1859,"interventions":1862},"NCT01109914","Mucosal Response in Immunocompromised Host",[88],"2015-03","2010-04",[1860,1861],"Kidney Transplantation","Immunity",[1841],{"trials":1864,"activeCount":97},[],{"intervention":1445,"totalTrials":121,"cells":1866},{"EARLY_PHASE1":1867,"PHASE1":1869,"PHASE2":1871,"PHASE3":1873,"PHASE4":1875,"NA":1881},{"trials":1868,"activeCount":97},[],{"trials":1870,"activeCount":97},[],{"trials":1872,"activeCount":97},[],{"trials":1874,"activeCount":97},[],{"trials":1876,"activeCount":97},[1877],{"nctId":1435,"briefTitle":1436,"status":314,"phases":1878,"primaryCompletion":1438,"completion":1439,"start":1440,"enrollment":1311,"conditions":1879,"interventions":1880},[88],[1442,1443],[1445,1410],{"trials":1882,"activeCount":97},[],{"intervention":1884,"totalTrials":121,"cells":1885},"Rocuronium",{"EARLY_PHASE1":1886,"PHASE1":1888,"PHASE2":1890,"PHASE3":1892,"PHASE4":1894,"NA":1905},{"trials":1887,"activeCount":97},[],{"trials":1889,"activeCount":97},[],{"trials":1891,"activeCount":97},[],{"trials":1893,"activeCount":97},[],{"trials":1895,"activeCount":97},[1896],{"nctId":1897,"briefTitle":1898,"status":314,"phases":1899,"primaryCompletion":1320,"completion":1320,"start":1900,"enrollment":1901,"conditions":1902,"interventions":1904},"NCT02553629","Effect of Deep Neuromuscular Block on Surgical Conditions in Morbidly Obese Patients",[88],"2015-09",109,[1903],"Surgical Conditions",[1884],{"trials":1906,"activeCount":97},[],{"intervention":1908,"totalTrials":121,"cells":1909},"AUC monitored withdrawal of MMF or CNI",{"EARLY_PHASE1":1910,"PHASE1":1912,"PHASE2":1914,"PHASE3":1916,"PHASE4":1918,"NA":1929},{"trials":1911,"activeCount":97},[],{"trials":1913,"activeCount":97},[],{"trials":1915,"activeCount":97},[],{"trials":1917,"activeCount":97},[],{"trials":1919,"activeCount":97},[1920],{"nctId":1921,"briefTitle":1922,"status":314,"phases":1923,"primaryCompletion":1924,"completion":1924,"start":1925,"enrollment":1926,"conditions":1927,"interventions":1928},"NCT00169910","VIP: Vascular Imaging Project. Study on the Progression of Cardiovascular Disease in Renal Transplant Recipients",[88],"2010-12","2005-12",119,[1371],[1908],{"trials":1930,"activeCount":97},[],{"intervention":1932,"totalTrials":121,"cells":1933},"Acetylsalicylic acid",{"EARLY_PHASE1":1934,"PHASE1":1936,"PHASE2":1938,"PHASE3":1940,"PHASE4":1942,"NA":1955},{"trials":1935,"activeCount":97},[],{"trials":1937,"activeCount":97},[],{"trials":1939,"activeCount":97},[],{"trials":1941,"activeCount":97},[],{"trials":1943,"activeCount":97},[1944],{"nctId":1945,"briefTitle":1946,"status":314,"phases":1947,"primaryCompletion":1948,"completion":1948,"start":1949,"enrollment":1950,"conditions":1951,"interventions":1953},"NCT01379079","Aspirin in Reduction of Tension II Study",[88],"2013-10","2011-04",290,[1952,18],"Hypertension",[1932,1954],"Acetylsalicylic acid lysinate",{"trials":1956,"activeCount":97},[],{"intervention":1954,"totalTrials":121,"cells":1958},{"EARLY_PHASE1":1959,"PHASE1":1961,"PHASE2":1963,"PHASE3":1965,"PHASE4":1967,"NA":1973},{"trials":1960,"activeCount":97},[],{"trials":1962,"activeCount":97},[],{"trials":1964,"activeCount":97},[],{"trials":1966,"activeCount":97},[],{"trials":1968,"activeCount":97},[1969],{"nctId":1945,"briefTitle":1946,"status":314,"phases":1970,"primaryCompletion":1948,"completion":1948,"start":1949,"enrollment":1950,"conditions":1971,"interventions":1972},[88],[1952,18],[1932,1954],{"trials":1974,"activeCount":97},[],{"intervention":1976,"totalTrials":121,"cells":1977},"fluticasone 500 mcg",{"EARLY_PHASE1":1978,"PHASE1":1980,"PHASE2":1982,"PHASE3":1984,"PHASE4":1986,"NA":1999},{"trials":1979,"activeCount":97},[],{"trials":1981,"activeCount":97},[],{"trials":1983,"activeCount":97},[],{"trials":1985,"activeCount":97},[],{"trials":1987,"activeCount":97},[1988],{"nctId":1989,"briefTitle":1990,"status":1991,"phases":1992,"completion":1993,"start":1994,"enrollment":1548,"conditions":1995,"interventions":1997},"NCT00158847","Modification Of Disease Outcome In COPD","TERMINATED",[88],"2005-05","2000-04",[1996],"Chronic Obstructive Pulmonary Disease",[1976,1998],"fluticasone 500 mcg + salmeterol 50 mcg",{"trials":2000,"activeCount":97},[],{"intervention":1998,"totalTrials":121,"cells":2002},{"EARLY_PHASE1":2003,"PHASE1":2005,"PHASE2":2007,"PHASE3":2009,"PHASE4":2011,"NA":2017},{"trials":2004,"activeCount":97},[],{"trials":2006,"activeCount":97},[],{"trials":2008,"activeCount":97},[],{"trials":2010,"activeCount":97},[],{"trials":2012,"activeCount":97},[2013],{"nctId":1989,"briefTitle":1990,"status":1991,"phases":2014,"completion":1993,"start":1994,"enrollment":1548,"conditions":2015,"interventions":2016},[88],[1996],[1976,1998],{"trials":2018,"activeCount":97},[],{"intervention":2020,"totalTrials":28,"cells":2021},"SGM-101",{"EARLY_PHASE1":2022,"PHASE1":2024,"PHASE2":2026,"PHASE3":2069,"PHASE4":2083,"NA":2085},{"trials":2023,"activeCount":97},[],{"trials":2025,"activeCount":97},[],{"trials":2027,"activeCount":97},[2028,2048,2058],{"nctId":2029,"briefTitle":2030,"status":153,"phases":2031,"primaryCompletion":71,"completion":71,"start":2032,"enrollment":1182,"conditions":2033,"interventions":2047},"NCT04755920","SGM-101 in Colorectal Brain Metastases.",[86],"2024-01-01",[2034,2035,2036,2037,2038,2039,2040,2041,2042,2043,2044,2045,2046],"Rectal Neoplasms","Rectum Cancer","Colorectal Neoplasms","Brain Metastases","Brain Neoplasms","Brain Diseases","Brain Cancer","Brain Tumor","Intestinal Neoplasms","Gastrointestinal Neoplasms","Gastrointestinal Cancer","Gastrointestinal Disease","Intestinal Disease",[2020],{"nctId":2049,"briefTitle":2050,"status":153,"phases":2051,"primaryCompletion":2052,"completion":2053,"start":2054,"enrollment":1182,"conditions":2055,"interventions":2057},"NCT04737213","SGM-101 in Colorectal Lung Metastases",[86],"2021-11-01","2021-12-01","2020-11-01",[15,2056],"Metastatic Colon Cancer",[2020],{"nctId":2059,"briefTitle":2060,"status":153,"phases":2061,"primaryCompletion":2062,"completion":2063,"start":2064,"enrollment":717,"conditions":2065,"interventions":2068},"NCT06280690","SGM-101 Tumor Targeted Fluorescence Endoscopy in Rectal Polyps With Suspected T1 Adenocarcinoma or High Grade Dysplasia",[86],"2025-04-30","2025-07-30","2024-01-31",[15,2066,2067],"Image","Low Grade Dysplasia of Colon",[2020],{"trials":2070,"activeCount":97},[2071],{"nctId":2072,"briefTitle":2073,"status":153,"phases":2074,"primaryCompletion":2075,"completion":2076,"start":2077,"enrollment":2078,"conditions":2079,"interventions":2082},"NCT04642924","SGM-101 in Locally Advanced and Recurrent Rectal Cancer",[86,87],"2021-10","2023-10","2019-10-22",203,[2080,2081],"Rectal Cancer","Recurrent Rectal Cancer",[2020],{"trials":2084,"activeCount":97},[],{"trials":2086,"activeCount":97},[],{"intervention":2088,"totalTrials":93,"cells":2089},"rosiglitazone",{"EARLY_PHASE1":2090,"PHASE1":2092,"PHASE2":2094,"PHASE3":2096,"PHASE4":2116,"NA":2118},{"trials":2091,"activeCount":97},[],{"trials":2093,"activeCount":97},[],{"trials":2095,"activeCount":97},[],{"trials":2097,"activeCount":97},[2098,2108],{"nctId":2099,"briefTitle":2100,"status":1991,"phases":2101,"primaryCompletion":2102,"completion":2103,"start":2104,"enrollment":1248,"conditions":2105,"interventions":2107},"NCT00452166","Rosiglitazone and Insulin Resistance in Renally Impaired Patients",[87],"2008-03","2008-05","2007-04",[1621,2106],"Insulin Resistance",[2088],{"nctId":2109,"briefTitle":2110,"status":1018,"phases":2111,"completion":2112,"start":2104,"enrollment":1548,"conditions":2113,"interventions":2115},"NCT00169923","Anti-Inflammatory Effects of Rosiglitazone in Patients With Stage 4 and 5 Chronic Kidney Disease",[86,87],"2009-05",[1621,2114],"Inflammation",[2088],{"trials":2117,"activeCount":97},[],{"trials":2119,"activeCount":97},[],{"intervention":2121,"totalTrials":121,"cells":2122},"bone marrow derived mononuclear cells",{"EARLY_PHASE1":2123,"PHASE1":2125,"PHASE2":2127,"PHASE3":2129,"PHASE4":2142,"NA":2144},{"trials":2124,"activeCount":97},[],{"trials":2126,"activeCount":97},[],{"trials":2128,"activeCount":97},[],{"trials":2130,"activeCount":97},[2131],{"nctId":2132,"briefTitle":2133,"status":153,"phases":2134,"primaryCompletion":2135,"completion":2135,"start":2136,"enrollment":2137,"conditions":2138,"interventions":2141},"NCT00539266","Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia",[86,87],"2012-10","2007-10",108,[2139,2140],"Intermittent Claudication","Peripheral Vascular Diseases",[2121],{"trials":2143,"activeCount":97},[],{"trials":2145,"activeCount":97},[],{"intervention":2147,"totalTrials":121,"cells":2148},"ranibizumab",{"EARLY_PHASE1":2149,"PHASE1":2151,"PHASE2":2153,"PHASE3":2155,"PHASE4":2168,"NA":2170},{"trials":2150,"activeCount":97},[],{"trials":2152,"activeCount":97},[],{"trials":2154,"activeCount":97},[],{"trials":2156,"activeCount":97},[2157],{"nctId":2158,"briefTitle":2159,"status":153,"phases":2160,"primaryCompletion":2161,"start":2162,"enrollment":2163,"conditions":2164,"interventions":2166},"NCT00811200","Treatment Of Radiation Retinopathy Trial",[86,87],"2012-01","2009-09",220,[2165],"Uveal Melanoma",[2147,2167],"triamcinolone acetonide",{"trials":2169,"activeCount":97},[],{"trials":2171,"activeCount":97},[],{"intervention":2167,"totalTrials":121,"cells":2173},{"EARLY_PHASE1":2174,"PHASE1":2176,"PHASE2":2178,"PHASE3":2180,"PHASE4":2186,"NA":2188},{"trials":2175,"activeCount":97},[],{"trials":2177,"activeCount":97},[],{"trials":2179,"activeCount":97},[],{"trials":2181,"activeCount":97},[2182],{"nctId":2158,"briefTitle":2159,"status":153,"phases":2183,"primaryCompletion":2161,"start":2162,"enrollment":2163,"conditions":2184,"interventions":2185},[86,87],[2165],[2147,2167],{"trials":2187,"activeCount":97},[],{"trials":2189,"activeCount":97},[],{"intervention":2191,"totalTrials":121,"cells":2192},"Pyridostigmine",{"EARLY_PHASE1":2193,"PHASE1":2195,"PHASE2":2197,"PHASE3":2199,"PHASE4":2210,"NA":2212},{"trials":2194,"activeCount":97},[],{"trials":2196,"activeCount":97},[],{"trials":2198,"activeCount":97},[],{"trials":2200,"activeCount":97},[2201],{"nctId":2202,"briefTitle":2203,"status":153,"phases":2204,"primaryCompletion":2205,"completion":2205,"start":2206,"enrollment":939,"conditions":2207,"interventions":2208},"NCT05919407","Pyridostigmine and Amifampridine for Myasthenia Gravis",[87],"2024-09-22","2023-03-22",[25],[2191,2209],"Amifampridine (base) with modified release",{"trials":2211,"activeCount":97},[],{"trials":2213,"activeCount":97},[],{"intervention":2209,"totalTrials":121,"cells":2215},{"EARLY_PHASE1":2216,"PHASE1":2218,"PHASE2":2220,"PHASE3":2222,"PHASE4":2228,"NA":2230},{"trials":2217,"activeCount":97},[],{"trials":2219,"activeCount":97},[],{"trials":2221,"activeCount":97},[],{"trials":2223,"activeCount":97},[2224],{"nctId":2202,"briefTitle":2203,"status":153,"phases":2225,"primaryCompletion":2205,"completion":2205,"start":2206,"enrollment":939,"conditions":2226,"interventions":2227},[87],[25],[2191,2209],{"trials":2229,"activeCount":97},[],{"trials":2231,"activeCount":97},[],{"intervention":2233,"totalTrials":121,"cells":2234},"ICG-guided bowel perfusion assessment",{"EARLY_PHASE1":2235,"PHASE1":2237,"PHASE2":2239,"PHASE3":2241,"PHASE4":2256,"NA":2258},{"trials":2236,"activeCount":97},[],{"trials":2238,"activeCount":97},[],{"trials":2240,"activeCount":97},[],{"trials":2242,"activeCount":97},[2243],{"nctId":2244,"briefTitle":2245,"status":153,"phases":2246,"primaryCompletion":2247,"completion":2248,"start":2249,"enrollment":2250,"conditions":2251,"interventions":2255},"NCT04712032","Anastomotic Leakage and Value Of Indocyanine Green in Decreasing Leakage Rates",[87],"2022-07-01","2022-10-01","2020-07-01",978,[2252,2253,2254],"Colo-rectal Cancer","Crohn Disease","Resectable Colorectal Carcinoma",[2233],{"trials":2257,"activeCount":97},[],{"trials":2259,"activeCount":97},[],{"intervention":2261,"totalTrials":121,"cells":2262},"Ethinylestradiol\u002Flevonorgestrel",{"EARLY_PHASE1":2263,"PHASE1":2265,"PHASE2":2267,"PHASE3":2269,"PHASE4":2282,"NA":2284},{"trials":2264,"activeCount":97},[],{"trials":2266,"activeCount":97},[],{"trials":2268,"activeCount":97},[],{"trials":2270,"activeCount":97},[2271],{"nctId":2272,"briefTitle":2273,"status":153,"phases":2274,"primaryCompletion":1021,"completion":1021,"start":2275,"enrollment":2276,"conditions":2277,"interventions":2280},"NCT04007874","Oral Contraceptive Pill Compared With Vitamin E in Women With Migraine",[87],"2019-09-10",360,[2278,2279],"Migraine","Migraine;Menstrual",[2261,2281],"Vitamin E",{"trials":2283,"activeCount":97},[],{"trials":2285,"activeCount":97},[],{"intervention":2281,"totalTrials":121,"cells":2287},{"EARLY_PHASE1":2288,"PHASE1":2290,"PHASE2":2292,"PHASE3":2294,"PHASE4":2300,"NA":2302},{"trials":2289,"activeCount":97},[],{"trials":2291,"activeCount":97},[],{"trials":2293,"activeCount":97},[],{"trials":2295,"activeCount":97},[2296],{"nctId":2272,"briefTitle":2273,"status":153,"phases":2297,"primaryCompletion":1021,"completion":1021,"start":2275,"enrollment":2276,"conditions":2298,"interventions":2299},[87],[2278,2279],[2261,2281],{"trials":2301,"activeCount":97},[],{"trials":2303,"activeCount":97},[],{"intervention":161,"totalTrials":121,"cells":2305},{"EARLY_PHASE1":2306,"PHASE1":2308,"PHASE2":2310,"PHASE3":2312,"PHASE4":2318,"NA":2320},{"trials":2307,"activeCount":97},[],{"trials":2309,"activeCount":97},[],{"trials":2311,"activeCount":97},[],{"trials":2313,"activeCount":97},[2314],{"nctId":151,"briefTitle":152,"status":153,"phases":2315,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":2316,"interventions":2317},[87],[159],[161,162,67,140],{"trials":2319,"activeCount":97},[],{"trials":2321,"activeCount":97},[],{"intervention":162,"totalTrials":121,"cells":2323},{"EARLY_PHASE1":2324,"PHASE1":2326,"PHASE2":2328,"PHASE3":2330,"PHASE4":2336,"NA":2338},{"trials":2325,"activeCount":97},[],{"trials":2327,"activeCount":97},[],{"trials":2329,"activeCount":97},[],{"trials":2331,"activeCount":97},[2332],{"nctId":151,"briefTitle":152,"status":153,"phases":2333,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":2334,"interventions":2335},[87],[159],[161,162,67,140],{"trials":2337,"activeCount":97},[],{"trials":2339,"activeCount":97},[],{"intervention":2341,"totalTrials":121,"cells":2342},"4x Praziquantel",{"EARLY_PHASE1":2343,"PHASE1":2345,"PHASE2":2347,"PHASE3":2349,"PHASE4":2361,"NA":2363},{"trials":2344,"activeCount":97},[],{"trials":2346,"activeCount":97},[],{"trials":2348,"activeCount":97},[],{"trials":2350,"activeCount":97},[2351],{"nctId":2352,"briefTitle":2353,"status":314,"phases":2354,"primaryCompletion":2355,"completion":2355,"start":608,"enrollment":2356,"conditions":2357,"interventions":2359},"NCT02868385","Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST)",[87],"2019-01-14",167,[2358],"Schistosomiasis",[2341,2360],"1x Praziquantel",{"trials":2362,"activeCount":97},[],{"trials":2364,"activeCount":97},[],{"intervention":2360,"totalTrials":121,"cells":2366},{"EARLY_PHASE1":2367,"PHASE1":2369,"PHASE2":2371,"PHASE3":2373,"PHASE4":2379,"NA":2381},{"trials":2368,"activeCount":97},[],{"trials":2370,"activeCount":97},[],{"trials":2372,"activeCount":97},[],{"trials":2374,"activeCount":97},[2375],{"nctId":2352,"briefTitle":2353,"status":314,"phases":2376,"primaryCompletion":2355,"completion":2355,"start":608,"enrollment":2356,"conditions":2377,"interventions":2378},[87],[2358],[2341,2360],{"trials":2380,"activeCount":97},[],{"trials":2382,"activeCount":97},[],{"intervention":2384,"totalTrials":93,"cells":2385},"simvastatin",{"EARLY_PHASE1":2386,"PHASE1":2388,"PHASE2":2390,"PHASE3":2409,"PHASE4":2411,"NA":2413},{"trials":2387,"activeCount":97},[],{"trials":2389,"activeCount":97},[],{"trials":2391,"activeCount":97},[2392,2400],{"nctId":2393,"briefTitle":2394,"status":153,"phases":2395,"primaryCompletion":2396,"start":1858,"enrollment":1311,"conditions":2397,"interventions":2398},"NCT01110785","Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal Cancer",[86],"2012-04",[15],[2399,2384],"panitumumab",{"nctId":2401,"briefTitle":2402,"status":153,"phases":2403,"primaryCompletion":2404,"start":2405,"enrollment":1382,"conditions":2406,"interventions":2407},"NCT01190462","Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer",[86],"2012-08","2010-08",[15],[2408,2384],"cetuximab",{"trials":2410,"activeCount":97},[],{"trials":2412,"activeCount":97},[],{"trials":2414,"activeCount":97},[],{"intervention":2416,"totalTrials":93,"cells":2417},"mesenchymal stromal cells",{"EARLY_PHASE1":2418,"PHASE1":2420,"PHASE2":2431,"PHASE3":2444,"PHASE4":2446,"NA":2448},{"trials":2419,"activeCount":97},[],{"trials":2421,"activeCount":97},[2422],{"nctId":2423,"briefTitle":2424,"status":314,"phases":2425,"primaryCompletion":2426,"completion":2426,"start":1857,"enrollment":1182,"conditions":2427,"interventions":2430},"NCT02387151","Allogeneic Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients",[85],"2018-11",[2428,2429],"Rejection","Graft Loss",[2416],{"trials":2432,"activeCount":97},[2433],{"nctId":2434,"briefTitle":2435,"status":153,"phases":2436,"primaryCompletion":2437,"completion":1022,"start":2438,"enrollment":318,"conditions":2439,"interventions":2442},"NCT02057965","Mesenchymal Stromal Cell Therapy in Renal Recipients",[86],"2020-01","2014-03",[2440,2441],"Renal Transplant Rejection","Fibrosis",[2443],"Mesenchymal Stromal Cells",{"trials":2445,"activeCount":97},[],{"trials":2447,"activeCount":97},[],{"trials":2449,"activeCount":97},[],{"intervention":2451,"totalTrials":121,"cells":2452},"Interferon Alfa-2b",{"EARLY_PHASE1":2453,"PHASE1":2455,"PHASE2":2457,"PHASE3":2470,"PHASE4":2472,"NA":2474},{"trials":2454,"activeCount":97},[],{"trials":2456,"activeCount":97},[],{"trials":2458,"activeCount":97},[2459],{"nctId":2460,"briefTitle":2461,"status":314,"phases":2462,"primaryCompletion":2463,"start":2464,"enrollment":2465,"conditions":2466,"interventions":2468},"NCT01639885","Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer",[85,86],"2014-01","2011-08",15,[2467],"Recurrent Ovarian Cancer",[2451,2451,2469],"p53 SLP",{"trials":2471,"activeCount":97},[],{"trials":2473,"activeCount":97},[],{"trials":2475,"activeCount":97},[],{"intervention":2469,"totalTrials":121,"cells":2477},{"EARLY_PHASE1":2478,"PHASE1":2480,"PHASE2":2482,"PHASE3":2488,"PHASE4":2490,"NA":2492},{"trials":2479,"activeCount":97},[],{"trials":2481,"activeCount":97},[],{"trials":2483,"activeCount":97},[2484],{"nctId":2460,"briefTitle":2461,"status":314,"phases":2485,"primaryCompletion":2463,"start":2464,"enrollment":2465,"conditions":2486,"interventions":2487},[85,86],[2467],[2451,2451,2469],{"trials":2489,"activeCount":97},[],{"trials":2491,"activeCount":97},[],{"trials":2493,"activeCount":97},[],{"intervention":2495,"totalTrials":121,"cells":2496},"PARP inhibitor and Anti-PD-L1",{"EARLY_PHASE1":2497,"PHASE1":2499,"PHASE2":2501,"PHASE3":2515,"PHASE4":2517,"NA":2519},{"trials":2498,"activeCount":97},[],{"trials":2500,"activeCount":97},[],{"trials":2502,"activeCount":97},[2503],{"nctId":2504,"briefTitle":2505,"status":153,"phases":2506,"primaryCompletion":2507,"completion":2507,"start":2508,"enrollment":2509,"conditions":2510,"interventions":2514},"NCT03951415","Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer",[86],"2021-08-01","2019-07-08",55,[2511,2512,2513],"Endometrial Neoplasms","Uterine Neoplasms","Endometrium Cancer",[2495],{"trials":2516,"activeCount":97},[],{"trials":2518,"activeCount":97},[],{"trials":2520,"activeCount":97},[],{"intervention":2522,"totalTrials":121,"cells":2523},"CRGD-ZW800-1",{"EARLY_PHASE1":2524,"PHASE1":2526,"PHASE2":2528,"PHASE3":2540,"PHASE4":2542,"NA":2544},{"trials":2525,"activeCount":97},[],{"trials":2527,"activeCount":97},[],{"trials":2529,"activeCount":97},[2530],{"nctId":2531,"briefTitle":2532,"status":314,"phases":2533,"primaryCompletion":2534,"completion":2534,"start":2535,"enrollment":717,"conditions":2536,"interventions":2539},"NCT05518071","FLUOPANC-trial - Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1",[86],"2024-05-23","2022-11-09",[2537,2538],"Pancreas Adenocarcinoma","Cholangiocarcinoma",[2522],{"trials":2541,"activeCount":97},[],{"trials":2543,"activeCount":97},[],{"trials":2545,"activeCount":97},[],{"intervention":2547,"totalTrials":121,"cells":2548},"Minocycline",{"EARLY_PHASE1":2549,"PHASE1":2551,"PHASE2":2553,"PHASE3":2563,"PHASE4":2565,"NA":2567},{"trials":2550,"activeCount":97},[],{"trials":2552,"activeCount":97},[],{"trials":2554,"activeCount":97},[2555],{"nctId":2556,"briefTitle":2557,"status":153,"phases":2558,"primaryCompletion":2559,"completion":2559,"start":2560,"enrollment":132,"conditions":2561,"interventions":2562},"NCT05680389","Antibiotics Against Amyloid Angiopathy",[85,86],"2023-12-02","2020-12-02",[792],[2547],{"trials":2564,"activeCount":97},[],{"trials":2566,"activeCount":97},[],{"trials":2568,"activeCount":97},[],{"intervention":2570,"totalTrials":121,"cells":2571},"MEN-ACYW135 reduced-dose intradermal administration",{"EARLY_PHASE1":2572,"PHASE1":2574,"PHASE2":2576,"PHASE3":2588,"PHASE4":2590,"NA":2592},{"trials":2573,"activeCount":97},[],{"trials":2575,"activeCount":97},[],{"trials":2577,"activeCount":97},[2578],{"nctId":2579,"briefTitle":2580,"status":314,"phases":2581,"primaryCompletion":2582,"completion":2582,"start":2583,"enrollment":2584,"conditions":2585,"interventions":2587},"NCT01782066","Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines",[85,86],"2014-02","2013-01",12,[2586],"Meningococcal Disease",[2570],{"trials":2589,"activeCount":97},[],{"trials":2591,"activeCount":97},[],{"trials":2593,"activeCount":97},[],{"intervention":2595,"totalTrials":121,"cells":2596},"Pembrolizumab",{"EARLY_PHASE1":2597,"PHASE1":2599,"PHASE2":2601,"PHASE3":2613,"PHASE4":2615,"NA":2617},{"trials":2598,"activeCount":97},[],{"trials":2600,"activeCount":97},[],{"trials":2602,"activeCount":97},[2603],{"nctId":2604,"briefTitle":2605,"status":153,"phases":2606,"primaryCompletion":2607,"completion":2607,"start":113,"enrollment":1574,"conditions":2608,"interventions":2612},"NCT05761132","Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study",[86],"2025-02-01",[2609,2610,2611],"Vulva Cancer","Vulva Neoplasm","Squamous Cell Cancer",[2595],{"trials":2614,"activeCount":97},[],{"trials":2616,"activeCount":97},[],{"trials":2618,"activeCount":97},[],{"intervention":1273,"totalTrials":121,"cells":2620},{"EARLY_PHASE1":2621,"PHASE1":2623,"PHASE2":2625,"PHASE3":2631,"PHASE4":2633,"NA":2635},{"trials":2622,"activeCount":97},[],{"trials":2624,"activeCount":97},[],{"trials":2626,"activeCount":97},[2627],{"nctId":1263,"briefTitle":1264,"status":314,"phases":2628,"primaryCompletion":1266,"completion":1267,"start":1268,"enrollment":717,"conditions":2629,"interventions":2630},[86],[1270,1271],[1273,1254],{"trials":2632,"activeCount":97},[],{"trials":2634,"activeCount":97},[],{"trials":2636,"activeCount":97},[],{"intervention":2638,"totalTrials":121,"cells":2639},"SGM-101 op top of ICG",{"EARLY_PHASE1":2640,"PHASE1":2642,"PHASE2":2644,"PHASE3":2654,"PHASE4":2656,"NA":2658},{"trials":2641,"activeCount":97},[],{"trials":2643,"activeCount":97},[],{"trials":2645,"activeCount":97},[2646],{"nctId":2647,"briefTitle":2648,"status":153,"phases":2649,"primaryCompletion":131,"completion":1615,"start":2650,"enrollment":1182,"conditions":2651,"interventions":2653},"NCT05965817","Fluorescence-guided Resection Of Colorectal Liver Metastases Using SGM-101 and Indocyanine GREEN",[86],"2023-12-01",[15,2652,2066],"Liver Metastasis Colon Cancer",[2638],{"trials":2655,"activeCount":97},[],{"trials":2657,"activeCount":97},[],{"trials":2659,"activeCount":97},[],{"intervention":2661,"totalTrials":121,"cells":2662},"C1 Inhibitor, Human",{"EARLY_PHASE1":2663,"PHASE1":2665,"PHASE2":2667,"PHASE3":2680,"PHASE4":2682,"NA":2684},{"trials":2664,"activeCount":97},[],{"trials":2666,"activeCount":97},[],{"trials":2668,"activeCount":97},[2669],{"nctId":2670,"briefTitle":2671,"status":153,"phases":2672,"primaryCompletion":2673,"completion":1020,"start":2674,"enrollment":2675,"conditions":2676,"interventions":2679},"NCT04489160","Complement Inhibition: Attacking the Overshooting Inflammation @Fter Traumatic Brain Injury",[86],"2023-07","2021-02-25",106,[2677,2678],"Traumatic Brain Injury","Trauma, Head",[2661],{"trials":2681,"activeCount":97},[],{"trials":2683,"activeCount":97},[],{"trials":2685,"activeCount":97},[],{"intervention":2687,"totalTrials":121,"cells":2688},"Denosumab",{"EARLY_PHASE1":2689,"PHASE1":2691,"PHASE2":2693,"PHASE3":2708,"PHASE4":2710,"NA":2712},{"trials":2690,"activeCount":97},[],{"trials":2692,"activeCount":97},[],{"trials":2694,"activeCount":97},[2695],{"nctId":2696,"briefTitle":2697,"status":153,"phases":2698,"primaryCompletion":2699,"completion":1670,"start":2700,"enrollment":132,"conditions":2701,"interventions":2707},"NCT03605199","Denosumab in Subjects With Giant Cell Rich Tumors of Bone",[86],"2021-06","2018-06-18",[2702,2703,2704,2705,2706],"Aneurysmal Bone Cysts","Giant Cell Granuloma","Osteoblastoma","Chondroblastoma","Chondromyxoid Fibroma",[2687],{"trials":2709,"activeCount":97},[],{"trials":2711,"activeCount":97},[],{"trials":2713,"activeCount":97},[],{"intervention":2715,"totalTrials":121,"cells":2716},"Allogeneic MSC",{"EARLY_PHASE1":2717,"PHASE1":2719,"PHASE2":2721,"PHASE3":2733,"PHASE4":2735,"NA":2737},{"trials":2718,"activeCount":97},[],{"trials":2720,"activeCount":97},[],{"trials":2722,"activeCount":97},[2723],{"nctId":2724,"briefTitle":2725,"status":153,"phases":2726,"primaryCompletion":2727,"completion":2728,"start":2729,"enrollment":1248,"conditions":2730,"interventions":2732},"NCT04918706","Allogeneic MSC Treatment for Pulmonary Emphysema",[86],"2021-09-01","2022-06-01","2019-06-25",[2731,2443],"Pulmonary Emphysema",[2715],{"trials":2734,"activeCount":97},[],{"trials":2736,"activeCount":97},[],{"trials":2738,"activeCount":97},[],{"intervention":2740,"totalTrials":121,"cells":2741},"ARA290",{"EARLY_PHASE1":2742,"PHASE1":2744,"PHASE2":2746,"PHASE3":2758,"PHASE4":2760,"NA":2762},{"trials":2743,"activeCount":97},[],{"trials":2745,"activeCount":97},[],{"trials":2747,"activeCount":97},[2748],{"nctId":2749,"briefTitle":2750,"status":314,"phases":2751,"primaryCompletion":2752,"completion":2582,"start":2753,"enrollment":2754,"conditions":2755,"interventions":2757},"NCT02070783","Cognitive and Neural Effects of ARA290",[85,86],"2013-02","2012-02",36,[2756],"Depression",[2740],{"trials":2759,"activeCount":97},[],{"trials":2761,"activeCount":97},[],{"trials":2763,"activeCount":97},[],{"intervention":2765,"totalTrials":121,"cells":2766},"Rituximab with belimumab",{"EARLY_PHASE1":2767,"PHASE1":2769,"PHASE2":2771,"PHASE3":2780,"PHASE4":2782,"NA":2784},{"trials":2768,"activeCount":97},[],{"trials":2770,"activeCount":97},[],{"trials":2772,"activeCount":97},[2773],{"nctId":2774,"briefTitle":2775,"status":314,"phases":2776,"primaryCompletion":2777,"completion":2777,"start":2438,"enrollment":1617,"conditions":2778,"interventions":2779},"NCT02284984","Synergetic B-cell Immodulation in SLE",[86],"2018-10-31",[610],[2765],{"trials":2781,"activeCount":97},[],{"trials":2783,"activeCount":97},[],{"trials":2785,"activeCount":97},[],{"intervention":2787,"totalTrials":121,"cells":2788},"tocilizumab and interferon alpha 2-b",{"EARLY_PHASE1":2789,"PHASE1":2791,"PHASE2":2793,"PHASE3":2804,"PHASE4":2806,"NA":2808},{"trials":2790,"activeCount":97},[],{"trials":2792,"activeCount":97},[],{"trials":2794,"activeCount":97},[2795],{"nctId":2796,"briefTitle":2797,"status":314,"phases":2798,"primaryCompletion":1546,"completion":1546,"start":2799,"enrollment":2800,"conditions":2801,"interventions":2802},"NCT01637532","Feasibility of the Combination of Chemotherapy (Carbo\u002FCaelyx or Carbo\u002FDoxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer",[85,86],"2011-02",21,[2467],[2787,2803],"Carboplatin and Caelyx or doxorubicin",{"trials":2805,"activeCount":97},[],{"trials":2807,"activeCount":97},[],{"trials":2809,"activeCount":97},[],{"intervention":2803,"totalTrials":121,"cells":2811},{"EARLY_PHASE1":2812,"PHASE1":2814,"PHASE2":2816,"PHASE3":2822,"PHASE4":2824,"NA":2826},{"trials":2813,"activeCount":97},[],{"trials":2815,"activeCount":97},[],{"trials":2817,"activeCount":97},[2818],{"nctId":2796,"briefTitle":2797,"status":314,"phases":2819,"primaryCompletion":1546,"completion":1546,"start":2799,"enrollment":2800,"conditions":2820,"interventions":2821},[85,86],[2467],[2787,2803],{"trials":2823,"activeCount":97},[],{"trials":2825,"activeCount":97},[],{"trials":2827,"activeCount":97},[],{"intervention":2829,"totalTrials":121,"cells":2830},"sirolimus and cyclophosphamide",{"EARLY_PHASE1":2831,"PHASE1":2833,"PHASE2":2835,"PHASE3":2849,"PHASE4":2851,"NA":2853},{"trials":2832,"activeCount":97},[],{"trials":2834,"activeCount":97},[],{"trials":2836,"activeCount":97},[2837],{"nctId":2838,"briefTitle":2839,"status":314,"phases":2840,"primaryCompletion":2841,"completion":2841,"start":2842,"enrollment":318,"conditions":2843,"interventions":2848},"NCT02821507","Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma",[86],"2021-12","2014-06",[2844,2845,2846,2847],"Conventional Chondrosarcoma","Myxoid Liposarcoma","Mesenchymal Chondrosarcoma","Dedifferentiated Chondrosarcoma",[2829],{"trials":2850,"activeCount":97},[],{"trials":2852,"activeCount":97},[],{"trials":2854,"activeCount":97},[],{"intervention":2856,"totalTrials":121,"cells":2857},"mRNA-1273",{"EARLY_PHASE1":2858,"PHASE1":2860,"PHASE2":2862,"PHASE3":2875,"PHASE4":2877,"NA":2879},{"trials":2859,"activeCount":97},[],{"trials":2861,"activeCount":97},[],{"trials":2863,"activeCount":97},[2864],{"nctId":2865,"briefTitle":2866,"status":153,"phases":2867,"primaryCompletion":2868,"completion":2869,"start":2870,"enrollment":717,"conditions":2871,"interventions":2874},"NCT05315362","Establishing Immunogenicity and Safety of Needle-free Intradermal Delivery of mRNA COVID-19 Vaccine",[86],"2022-09-01","2023-05-01","2022-05-01",[2872,2873],"Vaccination; Infection","COVID-19",[2856],{"trials":2876,"activeCount":97},[],{"trials":2878,"activeCount":97},[],{"trials":2880,"activeCount":97},[],{"intervention":2882,"totalTrials":121,"cells":2883},"Zoledronic acid",{"EARLY_PHASE1":2884,"PHASE1":2886,"PHASE2":2888,"PHASE3":2900,"PHASE4":2902,"NA":2904},{"trials":2885,"activeCount":97},[],{"trials":2887,"activeCount":97},[],{"trials":2889,"activeCount":97},[2890],{"nctId":2891,"briefTitle":2892,"status":1991,"phases":2893,"primaryCompletion":2894,"completion":2895,"start":1547,"enrollment":2465,"conditions":2896,"interventions":2899},"NCT00889590","Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)",[86],"2015-05","2015-07",[2897,2898],"Giant Cell Tumor of Bone","Osteoclastoma",[2882],{"trials":2901,"activeCount":97},[],{"trials":2903,"activeCount":97},[],{"trials":2905,"activeCount":97},[],{"intervention":2907,"totalTrials":121,"cells":2908},"Afatinib",{"EARLY_PHASE1":2909,"PHASE1":2911,"PHASE2":2913,"PHASE3":2925,"PHASE4":2927,"NA":2929},{"trials":2910,"activeCount":97},[],{"trials":2912,"activeCount":97},[],{"trials":2914,"activeCount":97},[2915],{"nctId":2916,"briefTitle":2917,"status":314,"phases":2918,"primaryCompletion":2919,"completion":2919,"start":2920,"enrollment":2921,"conditions":2922,"interventions":2924},"NCT03083678","Afatinib in Locally Advanced and Metastatic Chordoma",[86],"2025-01-31","2018-06-21",43,[2923],"Chordoma",[2907],{"trials":2926,"activeCount":97},[],{"trials":2928,"activeCount":97},[],{"trials":2930,"activeCount":97},[],{"intervention":2399,"totalTrials":121,"cells":2932},{"EARLY_PHASE1":2933,"PHASE1":2935,"PHASE2":2937,"PHASE3":2943,"PHASE4":2945,"NA":2947},{"trials":2934,"activeCount":97},[],{"trials":2936,"activeCount":97},[],{"trials":2938,"activeCount":97},[2939],{"nctId":2393,"briefTitle":2394,"status":153,"phases":2940,"primaryCompletion":2396,"start":1858,"enrollment":1311,"conditions":2941,"interventions":2942},[86],[15],[2399,2384],{"trials":2944,"activeCount":97},[],{"trials":2946,"activeCount":97},[],{"trials":2948,"activeCount":97},[],{"intervention":2950,"totalTrials":121,"cells":2951},"rabies vaccine",{"EARLY_PHASE1":2952,"PHASE1":2954,"PHASE2":2956,"PHASE3":2967,"PHASE4":2969,"NA":2971},{"trials":2953,"activeCount":97},[],{"trials":2955,"activeCount":97},[],{"trials":2957,"activeCount":97},[2958],{"nctId":2959,"briefTitle":2960,"status":153,"phases":2961,"primaryCompletion":2962,"completion":2962,"start":2963,"enrollment":1248,"conditions":2964,"interventions":2966},"NCT02276625","One-visit Multi-site Intradermal Rabies Vaccination - Dose Finding",[86],"2016-02","2014-10",[2965],"Rabies Pre-exposure Prophylaxis",[2950],{"trials":2968,"activeCount":97},[],{"trials":2970,"activeCount":97},[],{"trials":2972,"activeCount":97},[],{"intervention":2974,"totalTrials":121,"cells":2975},"PEG-liposomal prednisolone sodium phosphate",{"EARLY_PHASE1":2976,"PHASE1":2978,"PHASE2":2980,"PHASE3":2994,"PHASE4":2996,"NA":2998},{"trials":2977,"activeCount":97},[],{"trials":2979,"activeCount":97},[],{"trials":2981,"activeCount":97},[2982],{"nctId":2983,"briefTitle":2984,"status":1991,"phases":2985,"primaryCompletion":2986,"completion":2986,"start":2987,"enrollment":1248,"conditions":2988,"interventions":2993},"NCT02495662","The LIPMAT Study: Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation",[86],"2018-05-30","2015-11",[2989,2990,2991,2992],"Renal Dialysis","Hemodynamics","Vascular Remodeling","Neointima",[2974],{"trials":2995,"activeCount":97},[],{"trials":2997,"activeCount":97},[],{"trials":2999,"activeCount":97},[],{"intervention":2408,"totalTrials":121,"cells":3001},{"EARLY_PHASE1":3002,"PHASE1":3004,"PHASE2":3006,"PHASE3":3012,"PHASE4":3014,"NA":3016},{"trials":3003,"activeCount":97},[],{"trials":3005,"activeCount":97},[],{"trials":3007,"activeCount":97},[3008],{"nctId":2401,"briefTitle":2402,"status":153,"phases":3009,"primaryCompletion":2404,"start":2405,"enrollment":1382,"conditions":3010,"interventions":3011},[86],[15],[2408,2384],{"trials":3013,"activeCount":97},[],{"trials":3015,"activeCount":97},[],{"trials":3017,"activeCount":97},[],{"intervention":3019,"totalTrials":121,"cells":3020},"Sorafenib",{"EARLY_PHASE1":3021,"PHASE1":3023,"PHASE2":3025,"PHASE3":3035,"PHASE4":3037,"NA":3039},{"trials":3022,"activeCount":97},[],{"trials":3024,"activeCount":97},[],{"trials":3026,"activeCount":97},[3027],{"nctId":3028,"briefTitle":3029,"status":314,"phases":3030,"start":2136,"enrollment":3031,"conditions":3032,"interventions":3034},"NCT00887107","Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma",[86],32,[3033],"Thyroid Cancer",[3019],{"trials":3036,"activeCount":97},[],{"trials":3038,"activeCount":97},[],{"trials":3040,"activeCount":97},[],{"intervention":3042,"totalTrials":121,"cells":3043},"doxycycline",{"EARLY_PHASE1":3044,"PHASE1":3046,"PHASE2":3048,"PHASE3":3059,"PHASE4":3061,"NA":3063},{"trials":3045,"activeCount":97},[],{"trials":3047,"activeCount":97},[],{"trials":3049,"activeCount":97},[3050],{"nctId":3051,"briefTitle":3052,"status":314,"phases":3053,"completion":3054,"start":3055,"enrollment":132,"conditions":3056,"interventions":3058},"NCT00538967","The Effect of Doxycycline on Matrix Metalloproteinase Expression and Activity in the Abdominal Aneurysm",[86],"2005-08","2002-05",[3057],"Aortic Aneurysm, Abdominal",[3042],{"trials":3060,"activeCount":97},[],{"trials":3062,"activeCount":97},[],{"trials":3064,"activeCount":97},[],{"intervention":3066,"totalTrials":121,"cells":3067},"Tumor Infiltrating Lymphocytes",{"EARLY_PHASE1":3068,"PHASE1":3070,"PHASE2":3072,"PHASE3":3085,"PHASE4":3087,"NA":3089},{"trials":3069,"activeCount":97},[],{"trials":3071,"activeCount":97},[],{"trials":3073,"activeCount":97},[3074],{"nctId":3075,"briefTitle":3076,"status":153,"phases":3077,"primaryCompletion":2507,"completion":2053,"start":3078,"enrollment":2584,"conditions":3079,"interventions":3081},"NCT04072263","Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer",[85,86],"2018-08-01",[3080],"Ovarian Cancer Recurrent",[3066,3082,3083,3084],"Interferon Alfa 2A","Carboplatin","Paclitaxel",{"trials":3086,"activeCount":97},[],{"trials":3088,"activeCount":97},[],{"trials":3090,"activeCount":97},[],{"intervention":3082,"totalTrials":121,"cells":3092},{"EARLY_PHASE1":3093,"PHASE1":3095,"PHASE2":3097,"PHASE3":3103,"PHASE4":3105,"NA":3107},{"trials":3094,"activeCount":97},[],{"trials":3096,"activeCount":97},[],{"trials":3098,"activeCount":97},[3099],{"nctId":3075,"briefTitle":3076,"status":153,"phases":3100,"primaryCompletion":2507,"completion":2053,"start":3078,"enrollment":2584,"conditions":3101,"interventions":3102},[85,86],[3080],[3066,3082,3083,3084],{"trials":3104,"activeCount":97},[],{"trials":3106,"activeCount":97},[],{"trials":3108,"activeCount":97},[],{"intervention":3083,"totalTrials":121,"cells":3110},{"EARLY_PHASE1":3111,"PHASE1":3113,"PHASE2":3115,"PHASE3":3121,"PHASE4":3123,"NA":3125},{"trials":3112,"activeCount":97},[],{"trials":3114,"activeCount":97},[],{"trials":3116,"activeCount":97},[3117],{"nctId":3075,"briefTitle":3076,"status":153,"phases":3118,"primaryCompletion":2507,"completion":2053,"start":3078,"enrollment":2584,"conditions":3119,"interventions":3120},[85,86],[3080],[3066,3082,3083,3084],{"trials":3122,"activeCount":97},[],{"trials":3124,"activeCount":97},[],{"trials":3126,"activeCount":97},[],{"intervention":3084,"totalTrials":121,"cells":3128},{"EARLY_PHASE1":3129,"PHASE1":3131,"PHASE2":3133,"PHASE3":3139,"PHASE4":3141,"NA":3143},{"trials":3130,"activeCount":97},[],{"trials":3132,"activeCount":97},[],{"trials":3134,"activeCount":97},[3135],{"nctId":3075,"briefTitle":3076,"status":153,"phases":3136,"primaryCompletion":2507,"completion":2053,"start":3078,"enrollment":2584,"conditions":3137,"interventions":3138},[85,86],[3080],[3066,3082,3083,3084],{"trials":3140,"activeCount":97},[],{"trials":3142,"activeCount":97},[],{"trials":3144,"activeCount":97},[],{"intervention":3146,"totalTrials":121,"cells":3147},"everolimus",{"EARLY_PHASE1":3148,"PHASE1":3150,"PHASE2":3152,"PHASE3":3164,"PHASE4":3166,"NA":3168},{"trials":3149,"activeCount":97},[],{"trials":3151,"activeCount":97},[],{"trials":3153,"activeCount":97},[3154],{"nctId":3155,"briefTitle":3156,"status":153,"phases":3157,"primaryCompletion":3158,"start":3159,"enrollment":3160,"conditions":3161,"interventions":3163},"NCT01118065","Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer",[86],"2012-05","2010-05",42,[3162],"Head and Neck Cancer",[3146],{"trials":3165,"activeCount":97},[],{"trials":3167,"activeCount":97},[],{"trials":3169,"activeCount":97},[],{"intervention":3171,"totalTrials":121,"cells":3172},"Olaparib Oral Product",{"EARLY_PHASE1":3173,"PHASE1":3175,"PHASE2":3177,"PHASE3":3191,"PHASE4":3193,"NA":3195},{"trials":3174,"activeCount":97},[],{"trials":3176,"activeCount":97},[],{"trials":3178,"activeCount":97},[3179],{"nctId":3180,"briefTitle":3181,"status":1991,"phases":3182,"primaryCompletion":3183,"completion":3183,"start":3184,"enrollment":9,"conditions":3185,"interventions":3190},"NCT04780945","Functional Analysis of BRCAness",[86],"2024-12-31","2019-01-21",[3186,3187,3188,3189],"Ovarian Neoplasm Epithelial","Homologous Recombination Deficiency","BRCA1 Mutation","BRCA2 Mutation",[3171],{"trials":3192,"activeCount":97},[],{"trials":3194,"activeCount":97},[],{"trials":3196,"activeCount":97},[],{"intervention":3198,"totalTrials":121,"cells":3199},"Encorafenib + Binimetinib",{"EARLY_PHASE1":3200,"PHASE1":3202,"PHASE2":3204,"PHASE3":3217,"PHASE4":3219,"NA":3221},{"trials":3201,"activeCount":97},[],{"trials":3203,"activeCount":97},[],{"trials":3205,"activeCount":97},[3206],{"nctId":3207,"briefTitle":3208,"status":153,"phases":3209,"primaryCompletion":3210,"completion":3210,"start":3211,"enrollment":3212,"conditions":3213,"interventions":3216},"NCT05767879","(Neo)Adjuvant BRAF\u002FMEK Inhibition in pN1c Melanoma",[86],"2026-01-01","2022-01-01",28,[3214,3215],"Melanoma Stage III","In-Transit Metastasis of Cutaneous Melanoma",[3198],{"trials":3218,"activeCount":97},[],{"trials":3220,"activeCount":97},[],{"trials":3222,"activeCount":97},[],{"intervention":3224,"totalTrials":121,"cells":3225},"Sm-p80 + GLA-SE Vaccine",{"EARLY_PHASE1":3226,"PHASE1":3228,"PHASE2":3230,"PHASE3":3243,"PHASE4":3245,"NA":3247},{"trials":3227,"activeCount":97},[],{"trials":3229,"activeCount":97},[],{"trials":3231,"activeCount":97},[3232],{"nctId":3233,"briefTitle":3234,"status":153,"phases":3235,"primaryCompletion":3236,"completion":3237,"start":3238,"enrollment":11,"conditions":3239,"interventions":3241},"NCT05999825","Sm-p80 Schistosomiasis Challenge Study",[86],"2025-04","2025-09","2024-09",[3240,2358],"Schistosoma Mansoni",[3224,3242],"Schistosoma mansoni infection",{"trials":3244,"activeCount":97},[],{"trials":3246,"activeCount":97},[],{"trials":3248,"activeCount":97},[],{"intervention":1425,"totalTrials":121,"cells":3250},{"EARLY_PHASE1":3251,"PHASE1":3253,"PHASE2":3255,"PHASE3":3261,"PHASE4":3263,"NA":3265},{"trials":3252,"activeCount":97},[],{"trials":3254,"activeCount":97},[],{"trials":3256,"activeCount":97},[3257],{"nctId":1419,"briefTitle":1420,"status":153,"phases":3258,"start":1422,"conditions":3259,"interventions":3260},[86],[23],[1425,1426,1427,1428,1429],{"trials":3262,"activeCount":97},[],{"trials":3264,"activeCount":97},[],{"trials":3266,"activeCount":97},[],{"intervention":1426,"totalTrials":121,"cells":3268},{"EARLY_PHASE1":3269,"PHASE1":3271,"PHASE2":3273,"PHASE3":3279,"PHASE4":3281,"NA":3283},{"trials":3270,"activeCount":97},[],{"trials":3272,"activeCount":97},[],{"trials":3274,"activeCount":97},[3275],{"nctId":1419,"briefTitle":1420,"status":153,"phases":3276,"start":1422,"conditions":3277,"interventions":3278},[86],[23],[1425,1426,1427,1428,1429],{"trials":3280,"activeCount":97},[],{"trials":3282,"activeCount":97},[],{"trials":3284,"activeCount":97},[],{"intervention":1427,"totalTrials":121,"cells":3286},{"EARLY_PHASE1":3287,"PHASE1":3289,"PHASE2":3291,"PHASE3":3297,"PHASE4":3299,"NA":3301},{"trials":3288,"activeCount":97},[],{"trials":3290,"activeCount":97},[],{"trials":3292,"activeCount":97},[3293],{"nctId":1419,"briefTitle":1420,"status":153,"phases":3294,"start":1422,"conditions":3295,"interventions":3296},[86],[23],[1425,1426,1427,1428,1429],{"trials":3298,"activeCount":97},[],{"trials":3300,"activeCount":97},[],{"trials":3302,"activeCount":97},[],{"intervention":1429,"totalTrials":121,"cells":3304},{"EARLY_PHASE1":3305,"PHASE1":3307,"PHASE2":3309,"PHASE3":3315,"PHASE4":3317,"NA":3319},{"trials":3306,"activeCount":97},[],{"trials":3308,"activeCount":97},[],{"trials":3310,"activeCount":97},[3311],{"nctId":1419,"briefTitle":1420,"status":153,"phases":3312,"start":1422,"conditions":3313,"interventions":3314},[86],[23],[1425,1426,1427,1428,1429],{"trials":3316,"activeCount":97},[],{"trials":3318,"activeCount":97},[],{"trials":3320,"activeCount":97},[],{"intervention":3322,"totalTrials":121,"cells":3323},"Oxycodone Hydrochloride",{"EARLY_PHASE1":3324,"PHASE1":3326,"PHASE2":3339,"PHASE3":3341,"PHASE4":3343,"NA":3345},{"trials":3325,"activeCount":97},[],{"trials":3327,"activeCount":97},[3328],{"nctId":3329,"briefTitle":3330,"status":153,"phases":3331,"primaryCompletion":3332,"completion":3333,"start":3334,"enrollment":2509,"conditions":3335,"interventions":3338},"NCT05730062","Influence of Oxycodone on Individuals Taking an SSRI",[85],"2025-01-15","2025-04-15","2023-03-15",[941,3336,3337],"Depressive Disorder","Anxiety Disorders",[3322],{"trials":3340,"activeCount":97},[],{"trials":3342,"activeCount":97},[],{"trials":3344,"activeCount":97},[],{"trials":3346,"activeCount":97},[],{"intervention":3348,"totalTrials":121,"cells":3349},"Fludrocortisone",{"EARLY_PHASE1":3350,"PHASE1":3352,"PHASE2":3362,"PHASE3":3364,"PHASE4":3366,"NA":3368},{"trials":3351,"activeCount":97},[],{"trials":3353,"activeCount":97},[3354],{"nctId":3355,"briefTitle":3356,"status":314,"phases":3357,"primaryCompletion":3358,"completion":3359,"start":3158,"enrollment":1574,"conditions":3360,"interventions":3361},"NCT01648998","Fludrocortisone and Information Processing in Healthy Volunteers",[85],"2013-06","2013-12",[2756],[3348],{"trials":3363,"activeCount":97},[],{"trials":3365,"activeCount":97},[],{"trials":3367,"activeCount":97},[],{"trials":3369,"activeCount":97},[],{"intervention":3371,"totalTrials":121,"cells":3372},"Dexamethasone",{"EARLY_PHASE1":3373,"PHASE1":3375,"PHASE2":3387,"PHASE3":3389,"PHASE4":3391,"NA":3393},{"trials":3374,"activeCount":97},[],{"trials":3376,"activeCount":97},[3377],{"nctId":3378,"briefTitle":3379,"status":314,"phases":3380,"primaryCompletion":3381,"completion":3381,"start":3382,"enrollment":1311,"conditions":3383,"interventions":3385},"NCT02776436","Reducing Dexamethasone Around Docetaxel Infusion",[85],"2020-11-20","2016-01",[23,3384],"Prostate Cancer",[3371,3386],"Prednisone",{"trials":3388,"activeCount":97},[],{"trials":3390,"activeCount":97},[],{"trials":3392,"activeCount":97},[],{"trials":3394,"activeCount":97},[],{"intervention":3386,"totalTrials":121,"cells":3396},{"EARLY_PHASE1":3397,"PHASE1":3399,"PHASE2":3405,"PHASE3":3407,"PHASE4":3409,"NA":3411},{"trials":3398,"activeCount":97},[],{"trials":3400,"activeCount":97},[3401],{"nctId":3378,"briefTitle":3379,"status":314,"phases":3402,"primaryCompletion":3381,"completion":3381,"start":3382,"enrollment":1311,"conditions":3403,"interventions":3404},[85],[23,3384],[3371,3386],{"trials":3406,"activeCount":97},[],{"trials":3408,"activeCount":97},[],{"trials":3410,"activeCount":97},[],{"trials":3412,"activeCount":97},[],{"intervention":1006,"totalTrials":121,"cells":3414},{"EARLY_PHASE1":3415,"PHASE1":3417,"PHASE2":3423,"PHASE3":3425,"PHASE4":3427,"NA":3429},{"trials":3416,"activeCount":97},[],{"trials":3418,"activeCount":97},[3419],{"nctId":997,"briefTitle":998,"status":153,"phases":3420,"primaryCompletion":1000,"completion":1001,"start":1002,"enrollment":318,"conditions":3421,"interventions":3422},[85],[1004],[1006,1007,1008],{"trials":3424,"activeCount":97},[],{"trials":3426,"activeCount":97},[],{"trials":3428,"activeCount":97},[],{"trials":3430,"activeCount":97},[],{"intervention":1007,"totalTrials":121,"cells":3432},{"EARLY_PHASE1":3433,"PHASE1":3435,"PHASE2":3441,"PHASE3":3443,"PHASE4":3445,"NA":3447},{"trials":3434,"activeCount":97},[],{"trials":3436,"activeCount":97},[3437],{"nctId":997,"briefTitle":998,"status":153,"phases":3438,"primaryCompletion":1000,"completion":1001,"start":1002,"enrollment":318,"conditions":3439,"interventions":3440},[85],[1004],[1006,1007,1008],{"trials":3442,"activeCount":97},[],{"trials":3444,"activeCount":97},[],{"trials":3446,"activeCount":97},[],{"trials":3448,"activeCount":97},[],{"intervention":3450,"totalTrials":121,"cells":3451},"Sunitinib",{"EARLY_PHASE1":3452,"PHASE1":3454,"PHASE2":3465,"PHASE3":3467,"PHASE4":3469,"NA":3471},{"trials":3453,"activeCount":97},[],{"trials":3455,"activeCount":97},[3456],{"nctId":3457,"briefTitle":3458,"status":314,"phases":3459,"primaryCompletion":1924,"completion":1924,"start":3460,"enrollment":2465,"conditions":3461,"interventions":3463},"NCT01743300","The Influence of Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib in Cancer Patients",[85],"2007-07",[3462],"Healthy",[3450,3464],"Midazolam",{"trials":3466,"activeCount":97},[],{"trials":3468,"activeCount":97},[],{"trials":3470,"activeCount":97},[],{"trials":3472,"activeCount":97},[],{"intervention":3464,"totalTrials":121,"cells":3474},{"EARLY_PHASE1":3475,"PHASE1":3477,"PHASE2":3483,"PHASE3":3485,"PHASE4":3487,"NA":3489},{"trials":3476,"activeCount":97},[],{"trials":3478,"activeCount":97},[3479],{"nctId":3457,"briefTitle":3458,"status":314,"phases":3480,"primaryCompletion":1924,"completion":1924,"start":3460,"enrollment":2465,"conditions":3481,"interventions":3482},[85],[3462],[3450,3464],{"trials":3484,"activeCount":97},[],{"trials":3486,"activeCount":97},[],{"trials":3488,"activeCount":97},[],{"trials":3490,"activeCount":97},[],{"intervention":3492,"totalTrials":121,"cells":3493},"autologous bone marrow derived mesenchymal stromal cells",{"EARLY_PHASE1":3494,"PHASE1":3496,"PHASE2":3507,"PHASE3":3509,"PHASE4":3511,"NA":3513},{"trials":3495,"activeCount":97},[],{"trials":3497,"activeCount":97},[3498],{"nctId":3499,"briefTitle":3500,"status":314,"phases":3501,"primaryCompletion":1760,"completion":3502,"start":3503,"enrollment":1182,"conditions":3504,"interventions":3506},"NCT01306513","Safety and Feasibility Study of Administration of Mesenchymal Stemcells for Treatment of Emphysema",[85],"2012-11","2010-10",[3505],"Emphysema",[3492],{"trials":3508,"activeCount":97},[],{"trials":3510,"activeCount":97},[],{"trials":3512,"activeCount":97},[],{"trials":3514,"activeCount":97},[],{"intervention":3516,"totalTrials":121,"cells":3517},"saline",{"EARLY_PHASE1":3518,"PHASE1":3520,"PHASE2":3532,"PHASE3":3534,"PHASE4":3536,"NA":3538},{"trials":3519,"activeCount":97},[],{"trials":3521,"activeCount":97},[3522],{"nctId":3523,"briefTitle":3524,"status":314,"phases":3525,"primaryCompletion":3526,"completion":3526,"start":3527,"enrollment":300,"conditions":3528,"interventions":3530},"NCT01013558","New Options for Preoperative Anesthesia in Intrauterine Needling",[85],"2007-12","2004-09",[3529,30],"Stress",[3531,3516],"Remifentanil",{"trials":3533,"activeCount":97},[],{"trials":3535,"activeCount":97},[],{"trials":3537,"activeCount":97},[],{"trials":3539,"activeCount":97},[],{"intervention":3541,"totalTrials":121,"cells":3542},"GA2",{"EARLY_PHASE1":3543,"PHASE1":3556,"PHASE2":3558,"PHASE3":3560,"PHASE4":3562,"NA":3564},{"trials":3544,"activeCount":97},[3545],{"nctId":3546,"briefTitle":3547,"status":153,"phases":3548,"primaryCompletion":1021,"completion":1021,"start":3549,"enrollment":3550,"conditions":3551,"interventions":3552},"NCT05468606","Coadministration of GA2 Sporozoites With Adjuvants",[84],"2023-02-03",45,[855],[3541,3553,3554,3555],"BCG","YF-17D","Imiquimod",{"trials":3557,"activeCount":97},[],{"trials":3559,"activeCount":97},[],{"trials":3561,"activeCount":97},[],{"trials":3563,"activeCount":97},[],{"trials":3565,"activeCount":97},[],{"intervention":3553,"totalTrials":121,"cells":3567},{"EARLY_PHASE1":3568,"PHASE1":3574,"PHASE2":3576,"PHASE3":3578,"PHASE4":3580,"NA":3582},{"trials":3569,"activeCount":97},[3570],{"nctId":3546,"briefTitle":3547,"status":153,"phases":3571,"primaryCompletion":1021,"completion":1021,"start":3549,"enrollment":3550,"conditions":3572,"interventions":3573},[84],[855],[3541,3553,3554,3555],{"trials":3575,"activeCount":97},[],{"trials":3577,"activeCount":97},[],{"trials":3579,"activeCount":97},[],{"trials":3581,"activeCount":97},[],{"trials":3583,"activeCount":97},[],{"intervention":3554,"totalTrials":121,"cells":3585},{"EARLY_PHASE1":3586,"PHASE1":3592,"PHASE2":3594,"PHASE3":3596,"PHASE4":3598,"NA":3600},{"trials":3587,"activeCount":97},[3588],{"nctId":3546,"briefTitle":3547,"status":153,"phases":3589,"primaryCompletion":1021,"completion":1021,"start":3549,"enrollment":3550,"conditions":3590,"interventions":3591},[84],[855],[3541,3553,3554,3555],{"trials":3593,"activeCount":97},[],{"trials":3595,"activeCount":97},[],{"trials":3597,"activeCount":97},[],{"trials":3599,"activeCount":97},[],{"trials":3601,"activeCount":97},[],{"intervention":3555,"totalTrials":121,"cells":3603},{"EARLY_PHASE1":3604,"PHASE1":3610,"PHASE2":3612,"PHASE3":3614,"PHASE4":3616,"NA":3618},{"trials":3605,"activeCount":97},[3606],{"nctId":3546,"briefTitle":3547,"status":153,"phases":3607,"primaryCompletion":1021,"completion":1021,"start":3549,"enrollment":3550,"conditions":3608,"interventions":3609},[84],[855],[3541,3553,3554,3555],{"trials":3611,"activeCount":97},[],{"trials":3613,"activeCount":97},[],{"trials":3615,"activeCount":97},[],{"trials":3617,"activeCount":97},[],{"trials":3619,"activeCount":97},[],{"intervention":3621,"totalTrials":93,"cells":3622},"Deep neuromuscular block",{"EARLY_PHASE1":3623,"PHASE1":3625,"PHASE2":3627,"PHASE3":3629,"PHASE4":3631,"NA":3643},{"trials":3624,"activeCount":97},[],{"trials":3626,"activeCount":97},[],{"trials":3628,"activeCount":97},[],{"trials":3630,"activeCount":97},[],{"trials":3632,"activeCount":97},[3633],{"nctId":3634,"briefTitle":3635,"status":314,"phases":3636,"primaryCompletion":3637,"completion":3638,"start":3639,"enrollment":3640,"conditions":3641,"interventions":3642},"NCT03170661","Effect of Deep Versus Moderate Neuromuscular Block During Sevoflurane Anesthesia on Intraoperative Surgical Conditions.",[88],"2020-04-01","2020-06-01","2017-06-14",98,[1903],[3621],{"trials":3644,"activeCount":97},[3645],{"nctId":3646,"briefTitle":3647,"status":314,"phases":3648,"primaryCompletion":3649,"completion":3650,"start":3651,"enrollment":3652,"conditions":3653,"interventions":3657},"NCT03174223","Influence of Deep Versus Moderate Neuromuscular Blockade During General Anesthesia on 30-day Readmission Rates",[],"2018-06-01","2018-07-01","2017-06-01",460,[3654,3655,3656],"Postoperative Complications","Postoperative Wound Infection","Pneumonia",[3658],"deep neuromuscular block",{"intervention":3531,"totalTrials":93,"cells":3660},{"EARLY_PHASE1":3661,"PHASE1":3663,"PHASE2":3669,"PHASE3":3671,"PHASE4":3673,"NA":3675},{"trials":3662,"activeCount":97},[],{"trials":3664,"activeCount":97},[3665],{"nctId":3523,"briefTitle":3524,"status":314,"phases":3666,"primaryCompletion":3526,"completion":3526,"start":3527,"enrollment":300,"conditions":3667,"interventions":3668},[85],[3529,30],[3531,3516],{"trials":3670,"activeCount":97},[],{"trials":3672,"activeCount":97},[],{"trials":3674,"activeCount":97},[],{"trials":3676,"activeCount":97},[3677],{"nctId":3678,"briefTitle":3679,"status":314,"phases":3680,"primaryCompletion":2842,"completion":1321,"start":3681,"enrollment":3682,"conditions":3683,"interventions":3684},"NCT01912118","The Medasense Study",[89],"2013-07",96,[30],[3685,3531],"Propofol",{"intervention":3242,"totalTrials":93,"cells":3687},{"EARLY_PHASE1":3688,"PHASE1":3690,"PHASE2":3692,"PHASE3":3698,"PHASE4":3700,"NA":3702},{"trials":3689,"activeCount":97},[],{"trials":3691,"activeCount":97},[],{"trials":3693,"activeCount":97},[3694],{"nctId":3233,"briefTitle":3234,"status":153,"phases":3695,"primaryCompletion":3236,"completion":3237,"start":3238,"enrollment":11,"conditions":3696,"interventions":3697},[86],[3240,2358],[3224,3242],{"trials":3699,"activeCount":97},[],{"trials":3701,"activeCount":97},[],{"trials":3703,"activeCount":97},[3704],{"nctId":3705,"briefTitle":3706,"status":314,"phases":3707,"primaryCompletion":3708,"completion":3708,"start":3709,"enrollment":939,"conditions":3710,"interventions":3711},"NCT05085470","Repeated Controlled Human Schistosoma Mansoni Infection",[89],"2023-01-11","2021-10-29",[2358,3240],[3242],{"intervention":1819,"totalTrials":93,"cells":3713},{"EARLY_PHASE1":3714,"PHASE1":3716,"PHASE2":3718,"PHASE3":3720,"PHASE4":3722,"NA":3728},{"trials":3715,"activeCount":97},[],{"trials":3717,"activeCount":97},[],{"trials":3719,"activeCount":97},[],{"trials":3721,"activeCount":97},[],{"trials":3723,"activeCount":97},[3724],{"nctId":1807,"briefTitle":1808,"status":153,"phases":3725,"primaryCompletion":1810,"completion":1810,"start":1811,"enrollment":1812,"conditions":3726,"interventions":3727},[88],[1814,1815,1816],[1794,1818,1819],{"trials":3729,"activeCount":97},[3730],{"nctId":3731,"briefTitle":3732,"status":153,"phases":3733,"primaryCompletion":47,"completion":47,"start":3734,"enrollment":3735,"conditions":3736,"interventions":3737},"NCT05581420","Oral Versus Intravenous Iron in IBD Patients With Anti-inflammatory Therapy.",[89],"2022-06-02",152,[1814],[1819,3738],"MonoFer",{"intervention":3740,"totalTrials":93,"cells":3741},"Haloperidol",{"EARLY_PHASE1":3742,"PHASE1":3744,"PHASE2":3746,"PHASE3":3748,"PHASE4":3750,"NA":3752},{"trials":3743,"activeCount":97},[],{"trials":3745,"activeCount":97},[],{"trials":3747,"activeCount":97},[],{"trials":3749,"activeCount":97},[],{"trials":3751,"activeCount":97},[],{"trials":3753,"activeCount":97},[3754,3763],{"nctId":3755,"briefTitle":3756,"status":314,"phases":3757,"primaryCompletion":1717,"completion":1717,"start":3758,"enrollment":3759,"conditions":3760,"interventions":3762},"NCT00625014","Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans",[89],"2005-03",8,[2106,3761],"Dyslipidemia",[3740],{"nctId":3764,"briefTitle":3765,"status":314,"phases":3766,"primaryCompletion":3767,"completion":3767,"start":3768,"enrollment":3769,"conditions":3770,"interventions":3771},"NCT00625170","Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Antipsychotic Drugs in Healthy Humans",[89],"2004-12","2004-05",11,[2106,3761],[3772,3740],"olanzapine",{"intervention":3774,"totalTrials":121,"cells":3775},"Unfractionated heparin",{"EARLY_PHASE1":3776,"PHASE1":3778,"PHASE2":3780,"PHASE3":3782,"PHASE4":3784,"NA":3786},{"trials":3777,"activeCount":97},[],{"trials":3779,"activeCount":97},[],{"trials":3781,"activeCount":97},[],{"trials":3783,"activeCount":97},[],{"trials":3785,"activeCount":97},[],{"trials":3787,"activeCount":97},[3788],{"nctId":3789,"briefTitle":3790,"status":314,"phases":3791,"primaryCompletion":2248,"completion":2248,"start":3792,"enrollment":3793,"conditions":3794,"interventions":3796},"NCT05509647","Unfractionated Heparin in COVID-19 and Non-COVID-19 Patients",[],"2014-01-01",1500,[3795,2873],"Heparin Overdose of Undetermined Intent",[3774],{"intervention":3798,"totalTrials":121,"cells":3799},"Yellow Fever Vaccine",{"EARLY_PHASE1":3800,"PHASE1":3802,"PHASE2":3804,"PHASE3":3806,"PHASE4":3808,"NA":3810},{"trials":3801,"activeCount":97},[],{"trials":3803,"activeCount":97},[],{"trials":3805,"activeCount":97},[],{"trials":3807,"activeCount":97},[],{"trials":3809,"activeCount":97},[],{"trials":3811,"activeCount":97},[3812],{"nctId":3813,"briefTitle":3814,"status":153,"phases":3815,"primaryCompletion":3816,"completion":3817,"start":3818,"enrollment":1248,"conditions":3819,"interventions":3821},"NCT05901454","Yellow Fever Human Infection Model With YF-17D",[89],"2023-07-01","2024-03-01","2023-02-17",[3820],"Yellow Fever",[3798],{"intervention":3823,"totalTrials":121,"cells":3824},"3x 50 L3 larvae immunisation with albendazole treatment",{"EARLY_PHASE1":3825,"PHASE1":3827,"PHASE2":3829,"PHASE3":3831,"PHASE4":3833,"NA":3835},{"trials":3826,"activeCount":97},[],{"trials":3828,"activeCount":97},[],{"trials":3830,"activeCount":97},[],{"trials":3832,"activeCount":97},[],{"trials":3834,"activeCount":97},[],{"trials":3836,"activeCount":97},[3837],{"nctId":3838,"briefTitle":3839,"status":314,"phases":3840,"primaryCompletion":3841,"completion":3841,"start":3842,"enrollment":3843,"conditions":3844,"interventions":3845},"NCT03702530","Immunisation, Treatment and Controlled Human Hookworm Infection",[89],"2019-09-02","2018-12-17",23,[1054],[3823,3846],"2x 50 L3 larvae infection",{"intervention":3846,"totalTrials":121,"cells":3848},{"EARLY_PHASE1":3849,"PHASE1":3851,"PHASE2":3853,"PHASE3":3855,"PHASE4":3857,"NA":3859},{"trials":3850,"activeCount":97},[],{"trials":3852,"activeCount":97},[],{"trials":3854,"activeCount":97},[],{"trials":3856,"activeCount":97},[],{"trials":3858,"activeCount":97},[],{"trials":3860,"activeCount":97},[3861],{"nctId":3838,"briefTitle":3839,"status":314,"phases":3862,"primaryCompletion":3841,"completion":3841,"start":3842,"enrollment":3843,"conditions":3863,"interventions":3864},[89],[1054],[3823,3846],{"intervention":3866,"totalTrials":121,"cells":3867},"female Schistosoma mansoni cercariae",{"EARLY_PHASE1":3868,"PHASE1":3870,"PHASE2":3872,"PHASE3":3874,"PHASE4":3876,"NA":3878},{"trials":3869,"activeCount":97},[],{"trials":3871,"activeCount":97},[],{"trials":3873,"activeCount":97},[],{"trials":3875,"activeCount":97},[],{"trials":3877,"activeCount":97},[],{"trials":3879,"activeCount":97},[3880],{"nctId":3881,"briefTitle":3882,"status":314,"phases":3883,"primaryCompletion":3884,"completion":3885,"start":3886,"enrollment":3887,"conditions":3888,"interventions":3890},"NCT04269915","Single-sex Female Controlled Human Schistosomiasis Mansoni Infection",[89],"2022-04-14","2022-12-12","2020-08-12",13,[2358,3889],"Schistosomiasis Mansoni",[3866],{"intervention":3892,"totalTrials":121,"cells":3893},"Foceteria®",{"EARLY_PHASE1":3894,"PHASE1":3896,"PHASE2":3898,"PHASE3":3900,"PHASE4":3902,"NA":3904},{"trials":3895,"activeCount":97},[],{"trials":3897,"activeCount":97},[],{"trials":3899,"activeCount":97},[],{"trials":3901,"activeCount":97},[],{"trials":3903,"activeCount":97},[],{"trials":3905,"activeCount":97},[3906],{"nctId":3907,"briefTitle":3908,"status":314,"phases":3909,"primaryCompletion":3910,"completion":3910,"start":3911,"enrollment":3912,"conditions":3913,"interventions":3915},"NCT01066169","Vaccination Response in ImmunoCompromised Host. Immune Response After Vaccination Against Pandemic A\u002FH1N1 Influenza",[],"2010-02","2009-11",104,[3914],"HIV",[3892],{"intervention":3685,"totalTrials":121,"cells":3917},{"EARLY_PHASE1":3918,"PHASE1":3920,"PHASE2":3922,"PHASE3":3924,"PHASE4":3926,"NA":3928},{"trials":3919,"activeCount":97},[],{"trials":3921,"activeCount":97},[],{"trials":3923,"activeCount":97},[],{"trials":3925,"activeCount":97},[],{"trials":3927,"activeCount":97},[],{"trials":3929,"activeCount":97},[3930],{"nctId":3678,"briefTitle":3679,"status":314,"phases":3931,"primaryCompletion":2842,"completion":1321,"start":3681,"enrollment":3682,"conditions":3932,"interventions":3933},[89],[30],[3685,3531],{"intervention":3935,"totalTrials":121,"cells":3936},"Fraxiparine",{"EARLY_PHASE1":3937,"PHASE1":3939,"PHASE2":3941,"PHASE3":3943,"PHASE4":3945,"NA":3947},{"trials":3938,"activeCount":97},[],{"trials":3940,"activeCount":97},[],{"trials":3942,"activeCount":97},[],{"trials":3944,"activeCount":97},[],{"trials":3946,"activeCount":97},[],{"trials":3948,"activeCount":97},[3949],{"nctId":3950,"briefTitle":3951,"status":314,"phases":3952,"primaryCompletion":3953,"completion":3238,"start":3954,"enrollment":3955,"conditions":3956,"interventions":3958},"NCT02987946","Leiden Trial in Prevention of Post-Operative ThromboEmbolic Events",[89],"2023-12","2016-12",280,[3957],"Deep-Venous Thrombosis",[3935],{"intervention":3960,"totalTrials":121,"cells":3961},"Saliva collection at home",{"EARLY_PHASE1":3962,"PHASE1":3964,"PHASE2":3966,"PHASE3":3968,"PHASE4":3970,"NA":3972},{"trials":3963,"activeCount":97},[],{"trials":3965,"activeCount":97},[],{"trials":3967,"activeCount":97},[],{"trials":3969,"activeCount":97},[],{"trials":3971,"activeCount":97},[],{"trials":3973,"activeCount":97},[3974],{"nctId":3975,"briefTitle":3976,"status":153,"phases":3977,"primaryCompletion":2064,"completion":2064,"start":3978,"enrollment":1106,"conditions":3979,"interventions":3986},"NCT05722717","Genetic Risk Factors for Multi-system Inflammatory Syndrome in Children and Pediatric Post COVID Condition",[],"2022-06-28",[2873,3980,3981,3982,3983,3984,3985],"Post-Acute COVID-19","Post-Acute COVID19 Syndrome","Multi-System Inflammatory Syndrome in Children","Pediatric Inflammatory Multisystem Syndrome","Post COVID-19 Condition","Post-COVID-19 Syndrome",[3960],{"intervention":3988,"totalTrials":121,"cells":3989},"Pneumococcal Vaccine",{"EARLY_PHASE1":3990,"PHASE1":3992,"PHASE2":3994,"PHASE3":3996,"PHASE4":3998,"NA":4000},{"trials":3991,"activeCount":97},[],{"trials":3993,"activeCount":97},[],{"trials":3995,"activeCount":97},[],{"trials":3997,"activeCount":97},[],{"trials":3999,"activeCount":97},[],{"trials":4001,"activeCount":97},[4002],{"nctId":4003,"briefTitle":4004,"status":153,"phases":4005,"primaryCompletion":4006,"completion":4006,"start":4007,"enrollment":21,"conditions":4008,"interventions":4010},"NCT06202703","Fine Needle aSpiration of Lymph nodEs to Study vAccine-induced Immunity",[89],"2024-10-15","2023-04-15",[4009],"Vaccine-Preventable Diseases",[3988],{"intervention":4012,"totalTrials":121,"cells":4013},"Sequencing of DPYD gene",{"EARLY_PHASE1":4014,"PHASE1":4016,"PHASE2":4018,"PHASE3":4020,"PHASE4":4022,"NA":4024},{"trials":4015,"activeCount":97},[],{"trials":4017,"activeCount":97},[],{"trials":4019,"activeCount":97},[],{"trials":4021,"activeCount":97},[],{"trials":4023,"activeCount":97},[],{"trials":4025,"activeCount":97},[4026],{"nctId":4027,"briefTitle":4028,"status":153,"phases":4029,"primaryCompletion":4030,"completion":4031,"start":4032,"enrollment":4033,"conditions":4034,"interventions":4036},"NCT04300361","Identifying Novel Variants in the DPYD Gene in Patients of Non-Western Descent",[],"2022-03-01","2022-08-01","2020-03-01",600,[4035],"Neoplasms",[4012],{"intervention":4038,"totalTrials":121,"cells":4039},"Eptacog alfa",{"EARLY_PHASE1":4040,"PHASE1":4042,"PHASE2":4044,"PHASE3":4046,"PHASE4":4048,"NA":4050},{"trials":4041,"activeCount":97},[],{"trials":4043,"activeCount":97},[],{"trials":4045,"activeCount":97},[],{"trials":4047,"activeCount":97},[],{"trials":4049,"activeCount":97},[],{"trials":4051,"activeCount":97},[4052],{"nctId":4053,"briefTitle":4054,"status":314,"phases":4055,"primaryCompletion":4056,"completion":4057,"start":4058,"enrollment":4059,"conditions":4060,"interventions":4062},"NCT04723979","NovoSeven® in Severe Postpartum Haemorrhage - Experiences From UK, DK, FR, NL",[],"2021-01-01","2021-01-31","2020-05-01",3322,[4061],"Post Partum Hemorrhage",[4038],{"intervention":3738,"totalTrials":121,"cells":4064},{"EARLY_PHASE1":4065,"PHASE1":4067,"PHASE2":4069,"PHASE3":4071,"PHASE4":4073,"NA":4075},{"trials":4066,"activeCount":97},[],{"trials":4068,"activeCount":97},[],{"trials":4070,"activeCount":97},[],{"trials":4072,"activeCount":97},[],{"trials":4074,"activeCount":97},[],{"trials":4076,"activeCount":97},[4077],{"nctId":3731,"briefTitle":3732,"status":153,"phases":4078,"primaryCompletion":47,"completion":47,"start":3734,"enrollment":3735,"conditions":4079,"interventions":4080},[89],[1814],[1819,3738],{"intervention":4082,"totalTrials":121,"cells":4083},"VOILA",{"EARLY_PHASE1":4084,"PHASE1":4086,"PHASE2":4088,"PHASE3":4090,"PHASE4":4092,"NA":4094},{"trials":4085,"activeCount":97},[],{"trials":4087,"activeCount":97},[],{"trials":4089,"activeCount":97},[],{"trials":4091,"activeCount":97},[],{"trials":4093,"activeCount":97},[],{"trials":4095,"activeCount":97},[4096],{"nctId":4097,"briefTitle":4098,"status":153,"phases":4099,"primaryCompletion":4100,"completion":371,"start":4101,"enrollment":2163,"conditions":4102,"interventions":4104},"NCT05354310","The VOILA Intervention Study",[89],"2024-02-01","2022-02-01",[4103],"Aging",[4082],{"intervention":4106,"totalTrials":121,"cells":4107},"D-cycloserine",{"EARLY_PHASE1":4108,"PHASE1":4110,"PHASE2":4112,"PHASE3":4114,"PHASE4":4116,"NA":4118},{"trials":4109,"activeCount":97},[],{"trials":4111,"activeCount":97},[],{"trials":4113,"activeCount":97},[],{"trials":4115,"activeCount":97},[],{"trials":4117,"activeCount":97},[],{"trials":4119,"activeCount":97},[4120],{"nctId":4121,"briefTitle":4122,"status":314,"phases":4123,"primaryCompletion":4124,"completion":4124,"start":4125,"enrollment":4126,"conditions":4127,"interventions":4130},"NCT04762836","Pain, Learning, and Nocebo",[89],"2021-08-20","2021-02-28",53,[4128,4129],"Chronic Pain","Pain Syndrome",[4106],{"intervention":4132,"totalTrials":121,"cells":4133},"Rosuvastatin",{"EARLY_PHASE1":4134,"PHASE1":4136,"PHASE2":4138,"PHASE3":4140,"PHASE4":4142,"NA":4144},{"trials":4135,"activeCount":97},[],{"trials":4137,"activeCount":97},[],{"trials":4139,"activeCount":97},[],{"trials":4141,"activeCount":97},[],{"trials":4143,"activeCount":97},[],{"trials":4145,"activeCount":97},[4146],{"nctId":4147,"briefTitle":4148,"status":314,"phases":4149,"primaryCompletion":3954,"completion":3954,"start":4150,"enrollment":4151,"conditions":4152,"interventions":4153},"NCT01613794","Rosuvastatin Use to Improve the Coagulation Profile in Patients With Venous Thrombosis",[89],"2012-12",255,[32,20],[4132],{"intervention":4155,"totalTrials":121,"cells":4156},"Platelets",{"EARLY_PHASE1":4157,"PHASE1":4159,"PHASE2":4161,"PHASE3":4163,"PHASE4":4165,"NA":4167},{"trials":4158,"activeCount":97},[],{"trials":4160,"activeCount":97},[],{"trials":4162,"activeCount":97},[],{"trials":4164,"activeCount":97},[],{"trials":4166,"activeCount":97},[],{"trials":4168,"activeCount":97},[4169],{"nctId":4170,"briefTitle":4171,"status":314,"phases":4172,"primaryCompletion":4173,"completion":4173,"start":4174,"enrollment":4175,"conditions":4176,"interventions":4180},"NCT06043050","PRedicting OutcomeS in Preterm nEonates With thromboCyTopenia",[],"2024-04-30","2022-09-26",1042,[4177,4178,4179],"Neonatal Thrombocytopenia","Intraventricular Hemorrhage","Platelet Transfusion",[4155],{"intervention":4182,"totalTrials":121,"cells":4183},"Intravesical aminoglycoside instillations",{"EARLY_PHASE1":4184,"PHASE1":4186,"PHASE2":4188,"PHASE3":4190,"PHASE4":4192,"NA":4194},{"trials":4185,"activeCount":97},[],{"trials":4187,"activeCount":97},[],{"trials":4189,"activeCount":97},[],{"trials":4191,"activeCount":97},[],{"trials":4193,"activeCount":97},[],{"trials":4195,"activeCount":97},[4196],{"nctId":4197,"briefTitle":4198,"status":314,"phases":4199,"primaryCompletion":4200,"completion":4200,"start":4201,"enrollment":4202,"conditions":4203,"interventions":4206},"NCT05376670","Patient Satisfaction and Long-term Safety of Intravesical Aminoglycoside Instillations in UTI Prevention",[],"2023-03-07","2022-04-20",44,[4204,4205],"Urinary Tract Infections","Recurrent Urinary Tract Infection",[4182],{"intervention":4208,"totalTrials":121,"cells":4209},"Genetic analysis",{"EARLY_PHASE1":4210,"PHASE1":4212,"PHASE2":4214,"PHASE3":4216,"PHASE4":4218,"NA":4220},{"trials":4211,"activeCount":97},[],{"trials":4213,"activeCount":97},[],{"trials":4215,"activeCount":97},[],{"trials":4217,"activeCount":97},[],{"trials":4219,"activeCount":97},[],{"trials":4221,"activeCount":97},[4222],{"nctId":4223,"briefTitle":4224,"status":314,"phases":4225,"primaryCompletion":4226,"completion":4226,"start":4227,"enrollment":648,"conditions":4228,"interventions":4232},"NCT01940081","The Leiden Nonischemic Cardiomyopathy Study",[],"2019-09","2011-10",[4229,4230,4231],"Cardiomyopathy, Dilated","Tachycardia, Ventricular","Ventricular Fibrillation",[4208],{"intervention":4234,"totalTrials":121,"cells":4235},"Fluorescence guided identification using indocyanine green",{"EARLY_PHASE1":4236,"PHASE1":4238,"PHASE2":4240,"PHASE3":4242,"PHASE4":4244,"NA":4246},{"trials":4237,"activeCount":97},[],{"trials":4239,"activeCount":97},[],{"trials":4241,"activeCount":97},[],{"trials":4243,"activeCount":97},[],{"trials":4245,"activeCount":97},[],{"trials":4247,"activeCount":97},[4248],{"nctId":4249,"briefTitle":4250,"status":153,"phases":4251,"primaryCompletion":4252,"completion":4253,"start":4254,"enrollment":16,"conditions":4255,"interventions":4257},"NCT06155734","Fluorescence Guided Minimally-Invasive Resection Of Abdominal Paragangliomas Using Indocyanine Green",[],"2023-12-30","2024-02-20","2023-11-11",[4256],"Paraganglioma",[4234],{"intervention":4259,"totalTrials":121,"cells":4260},"Bevacizumab Zirconium Zr-89",{"EARLY_PHASE1":4261,"PHASE1":4263,"PHASE2":4265,"PHASE3":4267,"PHASE4":4269,"NA":4271},{"trials":4262,"activeCount":97},[],{"trials":4264,"activeCount":97},[],{"trials":4266,"activeCount":97},[],{"trials":4268,"activeCount":97},[],{"trials":4270,"activeCount":97},[],{"trials":4272,"activeCount":97},[4273],{"nctId":4274,"briefTitle":4275,"status":153,"phases":4276,"primaryCompletion":3183,"completion":3183,"start":4277,"enrollment":2465,"conditions":4278,"interventions":4280},"NCT05685836","89Zr-Bevacizumab PET\u002FCT Imaging in NF2 Patients",[],"2022-10-20",[4279],"Neurofibromatosis 2",[4259],{"intervention":3772,"totalTrials":121,"cells":4282},{"EARLY_PHASE1":4283,"PHASE1":4285,"PHASE2":4287,"PHASE3":4289,"PHASE4":4291,"NA":4293},{"trials":4284,"activeCount":97},[],{"trials":4286,"activeCount":97},[],{"trials":4288,"activeCount":97},[],{"trials":4290,"activeCount":97},[],{"trials":4292,"activeCount":97},[],{"trials":4294,"activeCount":97},[4295],{"nctId":3764,"briefTitle":3765,"status":314,"phases":4296,"primaryCompletion":3767,"completion":3767,"start":3768,"enrollment":3769,"conditions":4297,"interventions":4298},[89],[2106,3761],[3772,3740],{"intervention":4300,"totalTrials":121,"cells":4301},"Glyceryl trinitrate",{"EARLY_PHASE1":4302,"PHASE1":4304,"PHASE2":4306,"PHASE3":4308,"PHASE4":4310,"NA":4312},{"trials":4303,"activeCount":97},[],{"trials":4305,"activeCount":97},[],{"trials":4307,"activeCount":97},[],{"trials":4309,"activeCount":97},[],{"trials":4311,"activeCount":97},[],{"trials":4313,"activeCount":97},[4314],{"nctId":4315,"briefTitle":4316,"status":314,"phases":4317,"primaryCompletion":1320,"completion":1320,"start":4318,"enrollment":4319,"conditions":4320,"interventions":4327},"NCT04220606","1H Magnetic Resonance Spectroscopy in Migraine Patients",[89],"2015-04",39,[4321,4322,4323,4324,2039,4325,4326],"Migraine Disorders","Migraine Without Aura","Headache Disorders, Primary","Headache Disorders","Central Nervous System Diseases","Nervous System Diseases",[4300]]